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Background: Women affected by gynaecological cancer are often unaware of the sexual consequences
of both the cancer and its treatment. Most do not receive appropriate advice or help to recover sexual
function, and the effect on their sexuality may be profound, both physically and emotionally. However,
several potential therapies can be effective in helping recover some sexual engagement and change
self-perception around sex. A major initial challenge is informing and involving patients in an appropriate
and sensitive manner, and a further issue is delivering therapies in busy gynaelogical oncology clinics. This study
was conceived in response to a National Institute for Health Research (NIHR) Health Technology Assessment
(HTA) call asking for proposals to improve sexual functioning in women treated for gynaecological cancer
while taking into account associated issues of mood. Existing evidence-based therapies for improving sexual
function after cancer treatment were adapted and placed within a ‘stepped care‘ model for delivering these
in the NHS setting. An assessment and treatment stepping algorithm was developed in parallel, both to
assign women to a treatment level at assessment and to follow their progress session by session to advise
on changing intervention level. The assessment tool was applied to all participants on the principle that the
problem was sexual difficulty, not the cancer of origin.
Participants: Women aged > 18 years (with partners at their choice) treated for any gynaecological
malignancy with surgery and/or chemotherapy and/or radiation at University College London Hospital
or Bristol Gynaecological cancer centres, minimally 3 months post end of treatment, of any sexual
orientation, with sexual function difficulties identified by three initial screening questions.
Design: A feasibility two-arm, parallel-group randomised controlled pilot trial.
Setting: Two NHS gynaecological cancer centres, one in London and one in Bristol.
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Interventions: A three-level stepped care intervention.
Objective: To assess the feasibility of conducting a full-scale investigation of stepped therapy and indicate
the potential benefits to patients and to the NHS generally.
Primary outcome measures: Recruitment to study, proportion of women stepping up, number of usable
data points of all measures and time points over length of trial, and retention of participants to end
of trial.
Results: Development of the intervention and accompanying algorithm was completed. The study was
stopped before the recruitment stage and, hence, no randomisation, recruitment, numbers analysed,
outcomes or harms were recorded.
Limitations: As the study did not proceed, the intervention and its accompanying algorithm have not
been evaluated in practice, and the capacity of the NHS system to deliver it has not been examined.
Conclusions: None, as the study was halted.
Future work: The intervention could be studied within a clinical setting; however, the experience of the
study group points to the need for psychosocial studies in medical settings to establish pragmatic and
innovative mechanisms to ensure adequate resource when extending staff clinical skills and time to deliver
any new intervention for the duration of the trial.
Trial registration: Current Controlled Trials ISRCTN12010952 and ClinicalTrials.gov NCT02458001.
Funding: This project was funded by the NIHR HTA programme and will be published in full in Health
Technology Assessment; Vol. 23, No. 6. See the NIHR Journals Library website for further project
information.
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Women affected by gynaecological cancer are often unaware of the sexual consequences of thecancer and its treatment. Most do not receive appropriate help to recover sexual function, and the
physical and mental impact on their sexuality may be profound. However, several therapies could be
effective in helping recovery. A major initial challenge is informing and involving patients appropriately and
sensitively, and a further challenge is delivering therapies in busy cancer clinics. This study was conceived
in response to the funder‘s call asking for proposals to improve sexual functioning in women treated for
gynaecological cancer while taking into account associated issues of mood. Existing evidence-based
therapies for improving sexual function after gynaecological cancer treatment were adapted and a new
therapy for complex difficulties was devised. Three levels of intervention were developed and placed into
a ‘stepped care‘ model: a self-help intervention, a clinical nurse specialist-delivered intervention and a
clinical psychologist high-level intervention for problems not responding to levels 1 and 2. In parallel,
an assessment and treatment algorithm was developed to assess women and follow their progress closely
to inform whether or not their intervention level should be changed. However, major difficulties were
encountered: procedural and logistical delays in setting up the study, both at the beginning across a range
of hospitals and, later, at the point of training staff within the NHS to deliver the interventions within their
clinical workload. Issues such as maternity leave with untrained locum cover led to nursing staff being
unable to free up qualified staff to be part of the study. It is hoped that the existing developments can be
tested in a future study to determine (1) if they are effective and (2) whether or not they can be delivered
within the NHS.
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Women affected by gynaecological cancer are often not aware of the sexual consequences of both the
cancer and its treatment. Most do not receive appropriate advice or help to recover sexual function, and
the impact on their sexuality may be profound, both physically and mentally. However, there are several
potential therapies that can be effective in helping the recovery of at least some form of sexual activity.
A major initial challenge is informing and involving the patients in an appropriate and sensitive manner, and
a further issue is delivering such therapies in busy and often medically driven gynaecological oncology clinics.
This study was conceived in response to a National Institute for Health Research (NIHR) Health Technology
Assessment (HTA) programme call asking for proposals to improve sexual functioning in women treated for
gynaecological cancer while taking into account associated issues of mood. Existing evidence-based therapies
for improving sexual function after cancer treatment were adapted and placed within a ‘stepped care‘ model
for delivering these in the NHS setting. An assessment and treatment stepping algorithm was developed in
parallel, both to assign women to a level at assessment and, using sessional assessment, to follow their progress
closely to advise when to ‘step up‘ to another level. The assessment tool was applied to all participants on the
principle that the problem in question is sexual difficulty, not the cancer of origin.
Objectives
Aims
l To develop a stepped care psychosexual intervention [a Stepped Approach Intervention to Improve
Sexual Function after Gynaecological Cancer (SAFFRON)] on the Increasing Access to Psychological
Therapies (IAPT) model, together with a treatment algorithm for assigning women to levels of
intervention.
l To establish whether or not women treated for gynaecological cancer with moderate to severe sexual
dysfunction are willing to participate in a randomised trial model and adhere to treatment.
l To indicate likely rates of recruitment to a future evaluation of the SAFFRON intervention.
l To pilot a stepped care psychosexual intervention (SAFFRON) on the IAPT model.
l To establish whether or not the SAFFRON intervention is acceptable to patients.
l To establish whether or not SAFFRON is deliverable by a gynaelogical oncology cancer centre
multidisciplinary team.
l To indicate the most appropriate outcome measures for use in a larger trial.
l To inform estimates of the likely effect size, which will assist sample size calculations for a larger trial.
Research questions
l Are women treated for gynaecological cancer who develop moderate to severe sexual dysfunction
willing to participate in a randomised trial of treatment and adhere to that treatment?
l Will women agree to be randomised to an intervention to treat sexual dysfunction?
l Are different tumour sites, treatments and cancer stages at approach associated with different rates of
participation in the trial and uptake of the treatment?
l Is the stepped care system operable within the NHS system as it stands?
l What is the likely effect of the three levels of intervention on sexual function, mood and self-esteem,
as measured by standard measures?
l What is the rate of attrition from each treatment modality?
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Purpose of research
l Is it possible to design and pilot a randomised controlled trial (RCT) that can potentially answer the
question ‘Is SAFFRON a clinically and cost-effective treatment for sexual dysfunction occurring after
treatment for gynaecological cancer in the NHS?‘?
l Can the SAFFRON intervention be evaluated in a feasibility randomised trial?
l Is a stepped treatment approach acceptable and practical to women?
l Can it be done within NHS settings?
Methods
The call from NIHR HTA programme asked for a feasibility study. The study was to take place in two
phases. The first step was to be the development of a stepped intervention and a clinical algorithm to
use in determining progress through the steps. This intervention was then to be evaluated in a two-arm,
parallel-group, feasibility RCT. The results of this feasibility trial were to be used to inform a decision about
progressing to a full RCT.
The development of the stepped intervention was carried out by a team that combined the skills of
psychological therapy developers and evidence from the Cochrane review of existing interventions by Candy
et al. (Candy B, Jones L, Vickerstaff V, Tookman A, King M. Interventions for sexual dysfunction following
treatments for cancer in women. Cochrane Database Syst Rev 2016;2:CD005540), together with patient
involvement from the start.
A three-level intervention was decided on, using the IAPT model for treatment access for anxiety and depression
in general practice. Level 1 was simple self-help and level 2 was a taught face-to-face psychoeducation
intervention that was delivered by a study-trained clinical nurse specialists (CNSs) from a gynaelogical oncology
NHS team. The third level was a higher-level intervention for women with complex difficulties who had not
responded to lower-level help, which was to be delivered by a study trained clinical psychologist.
The level 1 (self-help) intervention was derived from an initial wide review of publicly available English-language
self-help materials on sex after cancer. All materials were reviewed by a subset of the project team and the
patient advocates. Two core documents were identified as the most detailed and pertinent to patients‘ needs.
They were rewritten to be appropriate for a UK audience, and for all sexual orientations, as well as to include
specifically gynaecological cancer-related material, as our patient advocates reported finding generic information,
with specific advice on other cancers, alienating. Both patient advocates contributed large amounts of material
at this point. An illustrated booklet was developed for the trial.
The level 2 intervention was adapted from an evidence-based clinical psychology intervention shown to
be effective in early endometrial and cervical cancer. It was rewritten to be delivered by CNSs with extra
training, and all materials and worksheets were adapted to cover the full range of gynaecological cancers
and their treatments, as well as the full trajectory of the cancer journey, including the palliative stage.
Training materials were written, and a full day‘s training was delivered in Bristol to a University College
London CNS and a Bristol radiotherapist to ensure identical training and to promote fidelity to the training
model. Both participants reported the need for more training and a desire for close supervision, finding the
areas of specific psychological therapy particularly difficult. This did not occur as the study was stopped.
The level 3 intervention for highly complex difficulties that had not responded to levels 1 and 2 was based on
interpersonal therapy (IPT). A new manual was written by an IPT trainer with experience of writing therapy
manuals, using input from patient advocates and a clinical psychologist experienced in gynaecological
oncology. Training was written and delivered to three clinical psycho-oncologists working in embedded
gynaecological cancer teams at both research sites in 1 day in London by Alessandra Lemma, a qualified IPT
SCIENTIFIC SUMMARY
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trainer. All reported finding the training an augmentation of their clinical skill set and were happy to pilot the
intervention with patients.
Measures were chosen for assessment that formed part of the algorithm and to answer the research
questions. Time points within the study were identified for assessment on a full range of measures and
the Female Sexual Function Index was chosen as the study measure to indicate response to the intervention.
Health economics measures were also included. A qualitative study was also planned to augment
understanding of barriers to implementation within the NHS, and interview schedules for participating
staff and patients were prepared.
Results
The study was closed by the funder, NIHR, in November 2015 because of slow progression to recruitment,
as well as changes to the protocol made after its original filing with NIHR that led to a substantial Research
Ethics Committee amendment. These had been recommended by the Trial Steering Committee, but had
not been notified to NIHR. There are therefore no results of the stepped care intervention with patients,
and the questions within the objectives cannot be answered here.
The stepped interventions were completed and training took place for both level 2 and level 3 staff.
The treatment algorithm was completed and all supporting study materials and documents were completed.
Conclusions
The study interventions and treatment algorithm were completed and could be used in a future study.
Patient involvement in this study made a major contribution and ideally any subsequent study would
continue this involvement.
Trial registration
This trial is registered as ISRCTN12010952 and ClinicalTrials.gov NCT02458001.
Funding
Funding for this study was provided by the HTA programme of the NIHR.
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Prevalence of sexual difficulties after cancer treatment
Many cancer patients are reported to have sexual difficulties.1,2 Gynaecological oncology patients are
particularly vulnerable to changes in sexual activity and lack of sexual desire,3–5 with sexual difficulty rates
estimated between 40% and 100%.6 Women undergo a range of treatments for ovarian, cervical, womb
and vulval cancer, with different combinations of surgery, chemotherapy and radiation. Some of these
treatments have a detrimental effect on women‘s internal and external sex organs, surrounding tissues
and nerves, and render some menopausal. Following such treatments women report a wide range of
difficulties including loss of libido, dyspareunia, vaginal dryness and orgasmic difficulty. In addition, the
symptom burden of gynaecological cancers is heavy, with many women reporting pain, fatigue, changes
in bowel function, urinary symptoms including leakage, and depression and anxiety,7 which interact with
menopausal and sexual difficulties.8 Hazewinkel et al.9 and Carpenter et al.10 both note the major effect of
physical well-being on sexual function, as well as the lack of relationship between extent of treatment and
formal scores of sexual function.
Other factors contributing to sexual problems
It is unsurprising that women treated for a gynaecological cancer are at high risk of emotional distress.
One prevalence study11 found that 23% satisfied criteria for major depressive disorder, and Parker et al.12
found greater depressive symptoms in gynaelogical oncology patients than in those with breast, urology
or gastrointestinal cancers.
Carpenter et al.10 suggest that some of this greater distress is related to the very high levels of sexual
difficulty experienced after treatment. They argue that sexual self-schema is an important moderator
of response. Self-schema is the set of beliefs and ideas that people have about themselves based on
their life experiences and, when this relates to the sexual domain, positive sexual self-schema (belief in and
expectation of themselves to be pleasurably sexual) is associated with more frequent sexual activity, better
sexual responsiveness and higher global sexual satisfaction across all disease sites,13,14 suggesting that it
makes women more resilient to the adverse sexual impacts of gynaecological cancer. Despite their sexual
difficulties, many gynaecological cancer survivors resume intercourse.13,15 Andersen et al.16 found that
frequency of intercourse in their sample was comparable with available norms for similarly aged women,
but these and other longitudinal data have shown sexual satisfaction17,18 and responsiveness16–20 to be
significantly impaired following treatment.
Professionals‘ response to sexual difficulties
Patients report that sexuality is rarely addressed by physicians.3 Lindau et al.18 found that conversation with
a physician about the sexual effects of cancer was associated with significantly lower likelihood of complex
sexual morbidity among very long-term survivors; however, 62% of 221 participants reported that their
physician had never initiated a discussion about sexuality after cancer. In their study of sexuality in a
palliative care setting, Vitrano et al.21 found that patients considered it important to talk about sexuality
and to face such an issue with an experienced professional, even though their life expectancy was short.
Patients in their study had not had this opportunity. Moreover, some patients were still able to maintain a
sufficient sexual activity, in terms of quality and quantity. Faithfull and White22 found that cancer nurses
were more likely to focus on the technical aspects of sexual recovery post treatment, for example vaginal
dilatation, and offered minimal advice or opportunities for disclosure of sexual dysfunctions, dissatisfaction
with partner relationships or mood and other psychological difficulties. Clinical nurse specialists (CNSs) in
gynaecological cancer acknowledge that they have an important role in this aspect of care but do not
always feel confident or competent to assess or manage patients‘ psychosexual needs, and appropriate
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referral is then problematic.23,24 Recently, a national psychosexual group of expert nurse ‘champions‘ has
been formed, and its work to date includes a psychosexual assessment guideline document for nurses.
Diagnosing and treating sexual dysfunction in this setting
Sexual dysfunctions are recognised as difficulties affecting both sexual desire and sexual response25 and six
apply to women, as defined by the Diagnostic and Statistical Manual of Mental Disorders:25–27
l sexual desire disorder or decreased libido – hypoactive sexual desire (low interest in sex)
l sexual aversion disorder – objections to having the genitals touched
l sexual arousal disorder
l orgasmic disorder – premature, delayed or absent orgasm following a normal sexual excitement phase
l sexual pain disorder of vaginismus – involuntary spasms of the muscles of the outer third of the vagina
that interfere with intercourse
l sexual pain disorder of dyspareunia – pain during intercourse.
A recent review28 of specific complaints of all cancer patients referred to the sexual health programme of
the Memorial Sloan Kettering Cancer Center found that the most common complaints for which patients
sought help were painful intercourse (65%), vaginal dryness (63%), low sexual desire (46%) and orgasmic
disorder (7%). The first two of these are partially managed through current best treatment, that is, topical
oestrogen, vaginal dilators and lubricants.2,29 Tsai et al.,30 using the Female Sexual Function Index (FSFI),
found that 66.7% of a Taiwanese sample of women with cervical cancer experienced sexual difficulties.
Many other studies report high rates of sexual difficulties, from 83% for overall general sexual difficulty,31
to 66% significant and 46% moderate sexual difficulties.32 Serati et al.,33 in a study of women with
early-stage cervix cancer treated with radical hysterectomy, reported that 65.8% of patients suffered
sexual dysfunction.
Interventions for sexual dysfunction after treatment for cancer
In contrast to the majority of sexual therapy interventions in which anxiety reduction is often key,
management of low sexual desire in the context of gynaecological cancer requires an intervention that
additionally addresses the wider range of mediating factors, including loss, life-threat, trauma, change
of body image, pre-existing psychological outlook, mood, depression and anxiety symptoms, as well as
the relationship in which the woman finds herself.34–37 Twenty-seven studies of sexual therapy interventions
after any cancer are reported in a systematic review by Brotto et al.,34 and Abbot-Anderson and Kwekkeboom35
found only three interventions specific to gynaecological cancer. These studies across a range of interventions
only show small effect sizes, despite patient satisfaction with the interventions. Flynn et al.,29 in their Cochrane
Review of randomised control interventions for psychosexual dysfunction in women treated for gynaecological
cancer, concluded that, ‘there is insufficient evidence to support or refute the use of any interventions for
psychosexual dysfunction after gynaecological cancer‘. Furthermore, they suggested that future investigations
required multicentre randomised controlled trials (RCTs) with outcome measures validated in gynaecological
cancer patients. They added specifically that ‘investigators should focus on interventions that can be delivered
by existing members of the multidisciplinary team treating women with gynaecological cancers. It is more likely
that such measures, if found effective, will be affordable and capable of being integrated into standard care‘.
Conclusions and need for the research
The evidence presented above shows that it is often the case that women affected by gynaecological cancer
are not aware of basic information about the sexual consequences of their gynaecological cancer and its
treatment, and do not receive appropriate advice or help to recover sexual function and to adapt to their
changed body and relationships. It is recognised by two Cochrane Reviews2,29 that new interventions are
needed for sexual dysfunction in gynaecological cancer, and these need to be examined in multicentre RCTs
with agreed outcome measures. There is a sizeable population with these problems to be addressed, for
there are currently 2 million people in England living with and beyond cancer of all types, and 2.5 million
across the UK as a whole.38 This number is likely to grow by > 3% per year, reflecting the increasing
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incidence of cancer and better survival rates. By 2030, there are likely to be around 3 million cancer survivors
in England,39 of whom a proportion will be survivors of gynaecological cancers. As we have the ability to
develop suitable treatments, we have a duty to explore them.39,40 The current acceptance of the worth of
well-being and, conversely, the cost of depression, anxiety or unwillingness to engage with the health-care
system – all potential long-term effects for the patient group concerned – are drivers of this research.41
Better awareness of mental health issues and depression in general42 and in cancer patients,43 plus greater
acceptance that these symptoms have causes that can be treated or addressed, is also relevant. In addition,
our work was planned at a time when there was more awareness of sexual health, and evidence from cancer
user groups,44 policy-makers45 and research46 of more openness to discuss these matters as a medical need.
The potential of CNSs to deliver interventions to help with the consequences of cancer treatment has been
recognised by the Department of Health and Social Care,47 yet little is known about CNSs‘ training or
supervisory needs to provide interventions for psychosexual dysfunction to work alongside psychologists.
If care pathways exist for addressing sexual dysfunction in cancer, they are currently unique to individual
units; providing the evidence for pathways that better meet the requirements of the population will facilitate
clinical application of more appropriate and consistent practice. What is currently missing from the literature
is a phased proposal that develops an intervention and tests this to facilitate best practice in the treatment
of sexual dysfunction for all relevant women in gynaecological cancer centres. This study was planned to
answer this question for the NHS by developing a stepped care intervention to be delivered within existing
NHS gynaelogical oncology services. A gynaelogical oncology CNS or radiographer was to deliver interventions
at step 1 and step 2 as the major treatment delivery, and only a small minority of more complex psychological
issues were to be treated at step 3 by a level 4 practitioner (a clinical psychologist or a psychiatrist), to whom
all patients should have access according to NHS guidance for psychological support in cancer.47,48
Objectives
Aims
l To develop a stepped care psychosexual intervention [a Stepped Approach Intervention to Improve
Sexual Function after Gynaecological Cancer (SAFFRON)] on the Increasing Access to Psychological
Therapies (IAPT) model together with a treatment algorithm for assigning women to levels of
intervention.
l To establish whether or not women treated for gynaecological cancer with moderate to severe sexual
dysfunction are willing to participate in a randomised trial and adhere to treatment.
l To indicate likely rates of recruitment to a future evaluation of the SAFFRON intervention.
l To pilot a stepped care psychosexual intervention (SAFFRON) on the IAPT model.49
l To establish whether or not the SAFFRON intervention is acceptable to patients.
l To establish whether or not SAFFRON is deliverable by a gynaelogical oncology cancer centre
multidisciplinary team.
l To indicate the most appropriate outcome measures for use in a larger trial.
l To inform estimates of the likely effect size, which will assist sample size calculations for a larger trial.
Research questions
l Are women treated for gynaecological cancer who develop moderate to severe sexual dysfunction
willing to participate in a randomised trial of treatment and adhere to that treatment?
l Will women agree to be randomised to an intervention to treat sexual dysfunction?
l Are different tumour sites, treatments and cancer stages at approach associated with different rates of
participation in the trial and uptake of the treatment?
l Is the stepped care system operable within the NHS system as it stands?
l What is the likely effect of the three levels of intervention on sexual function, mood and self-esteem as
measured by standard measures?
l What is the rate of attrition from each treatment modality?
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Purpose of research
l Is it possible to design and pilot a RCT that can potentially answer the question ‘Is SAFFRON a clinically
and cost-effective treatment for sexual dysfunction after treatment for gynaecological cancer in
the NHS?‘?
l Can the SAFFRON intervention be evaluated in a feasibility randomised trial?
l Is a stepped approach acceptable and practical?
l Can it be done within NHS settings?
Study design
The call from the National Institute for Health Research (NIHR) Health Technology Assessment (HTA)
programme asked for a feasibility study. The study was in the form of a two-arm, parallel-group RCT to
gain appropriate information to inform a decision about progressing to a full RCT.
Primary end points: measures of feasibility
l Recruitment rate in terms of number of women screened.
l Proportion of women stepping up from level 1 to level 2, and from level 2 to level 3.
l Proportion of women dropping out of therapy.
l Number of usable data points from all measures at all time points.
l Proportion of women lost to follow-up on trial measures.
Secondary end points
l Female Sexual Function Index score and Sexual Quality of Life (SQOL) Female score at 8 months
(accounting for baseline).
l Change in mood on Patient Health Questionnaire-9 items (PHQ-9) and Generalised Anxiety Disorder-7
(GAD-7).
l Change in quality of life on EuroQol-5 Dimensions, five-level version (EQ-5D-5L).
Process measures
l Satisfaction with interventions and preference for enrolment in one group over another, as measured
by bespoke questionnaires.
l Qualitative feedback from patients about their experience of participating in the trial, from interviews.
l Qualitative feedback from staff about implementation of study within clinics, from interviews.
Embedded qualitative study
The embedded qualitative study was to explore the attitudes towards participating in the study of both
staff and patient participants, and to examine potential barriers to and concerns about participation.
Interviews were planned with:
l trial participants in the intervention arm
l trial participants in the control arm
l participants who withdrew from the study
l staff who delivered the intervention
l staff in the clinics who were not involved in delivering the intervention.
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Patient and public involvement
Our study involved two patient advocates. Mrs Susan Dunning was a coapplicant and was involved from
the very beginning of conceiving the study. Mrs Val Madden joined once the study began and was,
together with Mrs Dunning, actively and energetically involved in project meetings and in feedback on the
development of the interventions. They gave the Trial Management Group valuable insight and direction
throughout the design of the trial and the development of the interventions and were supportive of the
entire endeavour.
Participating site selection
To assess the feasibility of recruiting sufficient numbers across the UK to inform a full RCT, two recruitment
settings were chosen. Both sites were gynaecological cancer centres with full CNS teams, and access to a
clinical psychologist who was embedded in the clinical team as opposed to being part of a generic psychology
department. This was to maximise recruitment to the feasibility trial and enable integration of a psychological
intervention study in the clinical teams.
University College London Hospitals NHS Foundation Trust (UCLH) Gynaecological Cancer Centre had
1839 women attending for a new diagnosis or follow-up in 2010.
Bristol Gynaecological Cancer Centre had an estimated pool of 1639 women attending in 2010.
These numbers were considered sufficient to support the required recruitment levels for the RCT.
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Chapter 2 Development of the SAFFRON
intervention
Methods
A key part of the conception of this study intervention was developing an intervention using the skills of
psychological therapy developers, together with patient involvement, from the start. Therefore, a team was
convened of psychological therapy professionals together with initially one patient advocate to the project,
Mrs Susan Dunning, who was a named coinvestigator as a result of her expression of interest, and later a
second patient advocate to the project, Mrs Val Madden. The involvement of patients was instrumental in
changing the character of the intervention, which moved from a close modelling on the IAPT stepped care
model to a more sequential one. Patient input was also key in changing language from a mental health
vocabulary to one recognising both the physical and the emotional causes of sexual dysfunction in this
population, and the interplay between them.
Mrs Susan Dunning was present at all project meetings, and she and Mrs Val Madden commented on all
aspects of the level 1 and 2 interventions. Professor Michael King and Dr Sue Gessler met with them both
to discuss in detail their views and input to the interventions at levels 1 and 2. Mrs Susan Dunning also
met with Professor Alessandra Lemma and Dr Sue Gessler to help inform the development of Interpersonal
Psychotherapy for Sexual Adjustment post Gynaecological Cancer (IPT-GO), and she and Mrs Val Madden
responded to and commented on early drafts of the IPT-GO manual.
Level 1
Members of the team took account of a Cochrane review of available literature,50 viewed pre publication,
and examined a wide range of publicly available material on sexuality after cancer written in English
from anglophone countries, and decided by consensus on two basic texts to work from.51,52 These were
commented on by project members, and reviewed in detail by Mrs Susan Dunning and Mrs Val Madden
from their experience and that of co-patients. The material was rewritten by Dr Sue Gessler, Professor
Michael King and Ms Karen Summerville and submitted to the project team, specifically Mrs Susan
Dunning and Mrs Val Madden, for further comments. The project team endorsed the final edited version.
Level 2
The level 2 intervention was derived from an evidence-based intervention aimed at early-stage cervix and
endometrial cancers with good prognosis, and was written for clinical psychologists to deliver.53 With
permission from Dr Lori Brotto, the copyright holder, the unpublished manual and worksheets (Brotto LA,
Heiman, JR. Sexual Health and Gynaecologic Cancer: Psychoeducation (PED) Treatment Manual. 2003)
were adapted by Dr Sue Gessler for this patient group, taking into account the full range of gynaecological
cancers and including all points of disease trajectory from initial follow-up through to receipt of palliative
input.1 The manual was also rewritten with greater explicitness to allow a CNS therapist without a clinical
psychology training to deliver the intervention. Both sections were submitted to the project team, specifically
Mrs Susan Dunning and Mrs Val Madden, for further comments. The project team endorsed the final
edited version.
Following the unexpected inability of both sites to allow a CNS to take part in the study, the team reviewed
possible staff in both sites. At UCLH a senior CNS from the Macmillan Support Centre was willing to be
involved, and at Bristol a senior radiographer who worked with post-treatment gynaecological cancer
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women on dilator use agreed to take part. This change of personnel required rewriting the manual to
take account of the disciplinary change. Training took into account this change of personnel. Dr Sue Gessler
presented a full day‘s training at one site (Bristol) to both level 2 practitioners together, and with both
research assistants (RAs) present, to promote equality of training and fidelity to the model. Training slides
were written for the full day, giving background to the study, and the practitioners were taken through the
sessions of the intervention using didactic teaching, role play and discussion. Feedback on their training was
gathered by the RAs to inform supervision and further skills development over the life of the study. Both
requested further direct training before beginning to see patients, reflecting on the difficulty of working
to a manualised intervention rather than using their generic patient skills. They also found some elements
of the psychological intervention challenging, such as taking a behavioural history of a sexual encounter.
Skype™ (Microsoft Corporation, Redmond, WA, USA) group supervision sessions were planned to allow
both level 2 therapists to be supervised together, to learn from each other and to maintain fidelity to the
model. Owing to the halting of the study, this did not take place.
Level 3
The full manual of IPT-GO was completed by Professor Alessandra Lemma with input from Dr Sue Gessler as
a specialist clinical psychologist in this area, and Mrs Susan Dunning and Mrs Val Madden as patient advocates.
The adaptation of interpersonal therapy (IPT) for a specific purpose followed the principles used by Professor
Alessandra Lemma in development of dynamic IPT.54 It fulfilled the basic elements of IPT but was reconceived
to take into account the physical changes and threats within a cancer diagnosis and its treatment. In particular,
the requirement of IPT to take on a ‘sick role‘ was transmuted in this version to acknowledge the cancer rather
than a mental health diagnosis such as depression.
A full day‘s training was given by Professor Alessandra Lemma to three clinical psychologists who specialised
in gynaecological oncology. The IPT core elements were taught in line with the national training programme
for IPT, and IPT-GO adaptations were then reviewed. Each clinical session was specifically covered. At the
end of training, all three gave feedback of feeling confident in delivering IPT-GO and all were assessed as
competent to deliver IPT-GO within the context of the trial. Trial conditions specified ongoing supervision
from Professor Alessandra Lemma, which was to be more frequent at the beginning of the trial and
lessening in frequency over time as competence increased and fidelity to the model was more assured.
Quality assurance and fidelity to model
Adherence to the model of intervention and protocol for delivery was planned to be monitored at all
steps. CNS and clinical psychologist sessions were to be taped and rated for adherence to the model using
standard techniques as used in the IAPT programme.55 We intended to seek consent from patients and
staff for anonymised versions of these to be available for subsequent analysis. The intervention team were
to receive regular supervision from seniors involving case discussions and reflection on specific difficulties
and challenges. The team were to be encouraged to feed back on gaps in their training and knowledge
so that these could be addressed. Field notes were to be taken so that detailed knowledge of training and
support needs could be developed; these could then be considered when developing the protocol for a
definitive trial. Supervision was to be based on a supervision to competency model, with more and closer
supervision at the beginning of the study, and supervisor observation, or auditing of tapes, of full sessions
at the early stages.
Fidelity was to be further measured by random tapes selected at the end of interventions that were to be
monitored by an independent rater.
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Status of intervention materials
Location and access
All intervention documents are archived at University College London (UCL). Level 1 contains elements
derived from a document for which the American Cancer Society holds copyright, and these are unable to
be reproduced in any form outside the study, including in this report and online.
Level 2 manual and worksheets can be obtained from either Dr Sue Gessler or Dr Lori Brotto on application
(this permission level is set by Dr Lori Brotto as the copyright holder).
Level 3, following the opinions of the Trial Steering Committee (TSC) and the project team, is not available
outside the prospect of an IPT training setting on ethical and intellectual property grounds and a prospective
study for its use in the gynaelogical oncology setting by appropriately trained individuals. Any such approach
should be made to Dr Sue Gessler or Professor Alessandra Lemma.
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Chapter 3 The SAFFRON feasibility two-arm,
parallel-group randomised controlled pilot trial
Introduction and background
The SAFFRON study was halted before recruitment began. However, the trial was set up with supporting
documentation and the planned methods and analysis are described in Methods and Analysis. The
methods also describe changes from the original protocol in response to ethics and the views of the TSC.
Methods
Inclusion criteria
l Women aged > 18 years (with partners at their choice) treated for any gynaecological malignancy with
surgery and/or chemotherapy and/or radiation at UCLH Gynaecological Cancer Centre or University
Hospitals Bristol Gynaecological Cancer Centre.
l ≥ 3 months post end of treatment.
l Any sexual orientation.
l With sexual function difficulties identified by initial screen (three clinical questions within clinical
interview posed by doctor or nurse).
Exclusion criteria
l Poor English.
l Current drug or alcohol abuse.
l Current sexual therapy or psychotherapy.
Justification for not limiting the study to one gynaecological cancer site
The HTA programme call asked for all gynaecological cancer types.
A recent systematic review35 advocated comprehensive and systematic assessment of sexual concerns
using reliable and valid measures in large representative samples that include all gynaecological cancer
diagnoses, stages of illness and types of treatment. Rees56 suggests a broader definition of sexual
satisfaction to be included in our level 2 and 3 interventions.
We used a person-centred, problem-based approach, as there is evidence that extent of treatment does
not necessarily correlate with sexual dysfunction.9,10
Participant recruitment
Accrual and attrition estimates
There were 365 new cancers diagnosed within UCLH in 2010, and 1474 follow-up patients were discussed
in the UCLH gynaelogical oncology multidisciplinary meeting that year (peer review report57), giving
approximately 100 attendances per week. Using published figures, over the 9-month recruitment period in
this study, approximately 550 eligible women were expected to be seen at UCLH [numbers are from UCLH
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figures that show that 1839 women were treated or in follow-up for a gynaecological cancer in 2010
(UCLH annual review 2010–11)].58 Following the literature,4,31,32 we estimated that 80% of these women who
were aged ≤ 75 years were likely to be sexually active, and previous publications indicate that a minimum of
50% of these were likely to have sexual dysfunction (see Chapter 1). We therefore expected that the sample
size for this feasibility study would be achievable in the 9-month period allowed for recruitment. The addition
of Bristol, whose throughput is broadly similar, should have aided effective recruitment. In 2011–12, 469 new
diagnoses, 23 recurrences and 14 metastases were discussed in the Bristol multidisciplinary meeting. Follow-up
consultations for Bristol were estimated at an additional 1000, thus offering an estimated pool of 1506
eligible women.
The length of the recruitment period was to ensure recruitment in the context of a busy clinic, bearing
in mind that asking all clinicians, both doctors and nurses, in two separate medical clinics to ask every
woman whether or not she had a sexual difficulty would require a major culture change.59
Justification of assumptions
Prevalence of sexual dysfunction in this population varies. Tsai et al.30 reported a prevalence of sexual
difficulties, according to the FSFI, of 66.67% in Asian women with cervical cancer. Other studies have
reported 83%31 to 66% for significant32 and 46% for moderate difficulties.32 Serati et al.33 reported a
prevalence of 65.8% among women with early-stage cervical cancer treated with radical hysterectomy.
We did not have figures for our population for those who were unpartnered and not in a sexual relationship.
We therefore assumed conservatively that an age-standardised rate of sexual difficulty in this population
would be 50% (i.e. would answer ‘yes‘ to the three opt-in questions; see Opt-in questions), and, of those
women, 50% would agree to enter the trial (based on the uptake of depression therapy trials in primary care).
El et al.60 found an 80% acceptance rate of a treatment intervention for depression in cancer.
Attrition rate
In the IAPT programme, Richards et al.49 reported an attrition rate of < 30% in psychological intervention
trials. We drew on this as a direct parallel; however, one of the outcomes of this feasibility work was to
assess how well we could minimise attrition.
Recruitment rate
We aimed to recruit two or three participants per week for 9 months across both sites (Figure 1).
All women attending a gynaecological oncology clinic following primary treatment for cancer in UCLH or
Bristol were potentially eligible.
Providing information on the trial was to take place during the clinical follow-up visit and to form an
integral part of the consultation.
Opt-in questions
Three clinical questions were to be asked by all clinicians (doctor or nurse) seeing a post-treatment
patient:
1. Are you having any sexual difficulties/problems in your intimate relationships?
2. Is this a problem for you?
3. Would you like some help with this?
Clinicians were able to choose how to word the opening question to suit their relationship with
the patient.
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ETAU arm (n = 50)Intervention arm (n =  50)
Not eligible and uninterested
Identify eligible women
Randomisation
T1: Baseline assessment of all measures
Level 1: self-help intervention booklet (CNS/radiographer) Level 1: self-help intervention booklet (CNS/radiographer)
Level 2: psychoeducation intervention (CNS/radiographer)
Level 3: interpersonal psychotherapy (clinical psychologist)
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T2: at 4 weeks FSFI and trial measures (RA)
T4: at 26−30 weeks trial measures (RA)
T5: at 8 months trial measures (RA) T5: at 8 months trial measures (RA)
T4: at 26−30 weeks trial measures (RA)
T3: at 10−14 weeks trial measures (RA)
T2: at 4 weeks FSFI and trial measures (RA)
T1: baseline a se sment of all measures
End of trial
FIGURE 1 Flow chart for intended study. ETAU, enhanced treatment as usual.
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If women responded affirmatively to all three questions, they were to be offered screening to the trial.
If they answered negatively to at least one question, or did not wish to answer, they were to continue
with treatment as usual (TAU).
If women consented to being informed about the trial with a view to screening for it, they were to see a
psychologically skilled RA, who would attend all clinics. The RA was to provide the patient information
leaflet [see Section 2 PDF; URL: www.journalslibrary.nihr.ac.uk/programmes/hta/1111102/#/ (accessed
December 2018)] and explain the nature of the trial.
Once informed, they were to wait a minimum of 24 hours for a cooling-off period before the RA approached
them for consent. The maximum period for consent was set as the length of the recruitment period of the trial;
that is, women were to be told that they could contact the RAs to discuss entry to the study at any point up
to the closure of recruitment, on the grounds that deciding to seek help for sexual difficulties often requires
thought, and associated anxiety might lead to avoidance for some time.
The initial screening of patients for entry to the trial was to be carried out by the RA using a paper
questionnaire, the FSFI,61 as well as questions on self-attributed reasons for any difficulties. Baser et al.62
recommend that studies with cancer patients establish self-attributed reasons, as the FSFI cannot
distinguish physical reasons from a concern regarding life-threatening illness as cause of low or absent
sexual activity. A cut-off score on the FSFI of 26 signifies sexual dysfunction (lower scores signify worse
sexual function).61,62
If patients scored ≤ 26 on the FSFI, they were eligible to enter the trial. If they scored > 26, they were to
be referred to a CNS for continued treatment.
Baseline assessment for the study was to be carried out by the RA at T1 (see Table 1).
Maximising recruitment
We identified clinical champions within the team and intended to consult them weekly to monitor and
explore concerns that might have arisen. Miss Adeola Olaitan (gynaecological oncologist) was a co-applicant
and former Tumour Board chairperson, Miss Jo Bailey (gynaecological oncologist) was the clinical lead
for Bristol, Miss Nicola Macdonald (gynaecological oncologist) was the clinical lead for UCLH and
Miss Karen Summerville was the lead CNS for UCLH and a co-applicant.63,64
Randomisation
Based on a randomisation specification document drawn up by the trial statisticians, a suitable web-based
randomisation system was organised by the PRIMENT Clinical Trials Unit, a UCL-based clinical trials unit
specialising in clinical trials in primary care and mental health. Randomisation was to be blocked (using
varying block size) to ensure equal numbers in each arm, and stratified by clinic site (UCLH and Bristol) to
ensure equal numbers of patients from these sites randomised to the intervention and control arms. After
a patient provided informed consent, the RA was to collect data and enter them into the randomisation
system to obtain the allocation for that patient. The patient would be informed of their allocation by the
RA, who would also inform the clinical team to mobilise either stepped care or enhanced routine care.
Breaking randomisation codes was not relevant here as patients and their clinical professionals would not
have been blinded to trial arm allocation.
Trial interventions
Treatment arm
The trial offered three interventions within a stepped care model to be compared with TAU. The three
interventions are described in detail in Chapter 2. The assessment is an integral part of the intervention
and is described below.
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Following submission to the Research Ethics Committee (REC), the REC requested the addition of level 1
(self-help booklet) to the TAU arm, given the low level of information and input generally available.
The control arm then became enhanced treatment as usual (ETAU).
The stepped care intervention was developed for this project based on previous evidence-based interventions.
Stepped care is widely used within psychological therapies and the IAPT programme,49 and this approach was
adapted for the gynaecological cancer setting to produce a three-step model including a clinical assessment.
Following the development of the interventions, it became necessary to convert to a sequential progress
through levels of intervention, owing to the essentially different content of each level.
l Level 1: self-help booklet written for the trial.
l Level 2: three- to five-session intervention based on the work of Brotto et al.53 This is an evidence-based
psychoeducational intervention previously delivered by clinical psychologists, adapted for a wider patient
group and to be delivered fortnightly by study-trained CNSs or brachytherapy radiographers with experience
in working with women post treatment, with taping and supervision for adherence to protocol and manual.
Patients are given worksheets and homework as an integral part of the intervention. There are at least three
sessions, with two possible follow-up consolidation sessions depending on specific areas of difficulty to be
decided by trial CNS/radiographer in collaboration with the woman.
l Level 3: 16 weekly sessions of manualised brief psychotherapy intervention, adapted from the high-
intensity National Institute for Health and Care Excellence-recommended therapy for depression IPT65
to be delivered by a study-trained clinical psychologist. The new intervention (IPT-GO) was adapted to
take account of specific issues concerning the body image and self-image and esteem of women, and
was written with input from the two patient advocates on the study.
Enhanced treatment as usual arm
Justification for enhanced treatment as usual versus treatment as usual
Level 1 consists of written material (newly combined and edited for the study) currently available on the
internet, but which most women do not access.51,52 It was to be given to women in both arms for the
following reasons:
l For ethics reasons, women who agreed to the study, and who were disclosing difficult and delicate
material, should receive some input that may be helpful.
l For recruitment reasons, every woman who entered the study should receive something not currently
widely available.
Enhanced treatment as usual
l Any woman who identified herself as having a sexual difficulty was to be referred to the CNS team,
in which she would be assigned to a gynaelogical oncology CNS who had not received specialist
psychosexual training.
l The CNS input was defined with both teams as including assessment of the difficulty, normalising the
experience, offering supportive counselling, helping her in discussing her relationship and advising on
topical lubricants and oestrogen.
l Women treated with radiation were to be seen in post-treatment nurse-led clinics at UCLH by CNSs, in
which they would be physically examined and taught to use dilators to keep their vaginal access patent.
The content of the point immediately above would occur at this point. At Bristol, trained radiotherapists
(not CNSs) were to follow up all women treated with radiotherapy, introduce dilators and cover the
same material as the above points.
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Women assigned to ETAU would only be seen by a naive CNS/radiographer (i.e. not trained in the
intervention). CNSs/radiographers trained in the intervention would be asked not to share the content of
the new interventions with their clinical colleagues, or include study interventions in the delivery of care
to non-trial patients. Materials were to be stored separately in locked cabinets and sessions were to be
conducted either in clinic rooms or, in the case of telephone sessions, in private rooms where colleague
CNSs/radiographers could not overhear the session.
All treatments in the ETAU arm were to be recorded from case notes and CNS/radiographer/psychologist
treatment files to characterise the interventions received. All participating women were to receive a
patient-held treatment diary in which they could log all treatment contact.
Assessment at intake prior to randomisation
l Female Sexual Function Index.
l Patient Health Questionnaire-9 items.
l Self-assessment of level of sexual activity and self-attributed reasons for difficulties.
Blinding and other measures taken to avoid bias
As is common in trials of complex health-care interventions, it was not possible for clinicians and patients to
be blinded to their assignment to treatment group. RAs on the trial would have needed to input group-specific
data into the online database, as well as informing participants of their allocation, so they could not be
blinded. The trial statistician was to remain masked until all data were collected and the final analysis plan was
agreed by the research team. To assess the possible leakage of any aspect of the new intervention into ETAU
(as both the intervention and the control arms were to be treated within a single centre), all participants in
both arms were to be asked at follow-up to describe any treatments or information they had accessed, as
some, by having the possibility of an intervention raised, may have been seeking treatment elsewhere. They
were to be assigned a treatment diary (similar to a chemotherapy diary) in which to record all health-care
contacts. This was to be cross-checked against clinical process data (outpatient clinic records, CNS databases
and records in both centres) by the researchers.
An important element of this trial, which could be avoided, was that there were likely to be women made
aware of the issue of sexual difficulty after treatment by doctors and nurses discussing the trial with them
within the two centres. Women made aware but randomised to usual care might well have decided to
seek out extra information and resources, or make more demands within usual care. This informed the
REC decision to request the introduction of the level 1 materials to the control arm, TAU, making the
control arm receive ETAU.
Process through levels of intervention
Figure 2 shows the flow chart for the intended study.
l All women who consented to be part of the study were to be assessed on the entry criteria.
l Entry to study required a FSFI score of ≤ 26 and self-rated sexual difficulty.
l All eligible women received level 1 booklet from RA (ETAU: justified in Description and justification of
the duration of treatment, subject participation and trial follow-up).
l All women were to be assessed at 4 weeks by RA following receipt of level 1 booklet.
l If the FSFI score was ≤ 26 after level 1, then intervention arm women progressed to level 2
(CNS/radiographer intervention).
l At completion of level 2 (three sessions attended), reassess. If the FSFI score was ≤ 26, offer level 3
intervention. If women failed to attend, RAs were to follow up if women had agreed during the
consent process.
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The primary outcome measure was the FSFI,61 an internationally recognised rating scale that allows women
to describe their sexual experience in a range of domains: desire, arousal, lubrication, orgasm, pain and
satisfaction. This was to be measured at T1, T4 and T5.
At all five time points the following were to be recorded by the RA:
l Economics – EQ-5D-5L of severity measures an individual‘s generic health status and allows the
computation of quality-adjusted life-years (QALYs) for the cost-effectiveness analysis. SQOL66 is a series of
statements about thoughts and feelings around sex life as a measure of sexual-related quality of life. The
SQOL also functioned as part of the treatment algorithm during the interventions, as the FSFI score was
the primary outcome measure for sexual function.
Start intervention
Level 1-Self Help Booklet
After 4 weeks,














FSFI (score of ≤ 26) 
After final session,
FSFI (score of ≤ 26) 
End of 
intervention
Level 3: IPT-GO intervention
(psychologist)
Level 2: psychoeducation 
(CNS/radiographer)
l 1: self-help booklet
FIGURE 2 Intervention flow chart for intended study.
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l Depression – PHQ-9 is a brief measure of depression severity.67 PHQ-9 scores of 5–9, 10–14, 15–19
and 20–27 represent mild, moderate, moderately severe and severe depression, respectively.
l Anxiety – GAD-7 is a brief self-report scale to identify probable cases of general anxiety disorder.68
Scores of 5–9, 10–14 and 15–21 represent mild, moderate and severe anxiety, respectively.
At other time points additional measures were to be completed:
l Client Services Receipt Inventory (CSRI) – our in-house adaptation of the CSRI to assess use of health
and social services.69 Data were to be collected at T1, T3 and T5.
l Preference measure – a one-item, bespoke questionnaire that asks participants to rate their preference
for intervention or ETAU groups on a seven-point Likert scale. Data were to be collected at T1, T3, T4
and T5 (see Description and justification of the duration of treatment, subject participation and trial
follow-up).
l Evaluation and Satisfaction Measure – a bespoke questionnaire that asks participants who have
completed the level 2 intervention to answer questions on satisfaction and adherence.
l At baseline (randomisation) the following additional demographic and clinical information was to be
recorded on a case report form by the RA –
¢ Demographics: ethnicity, current relationship status, occupation, education.
¢ Personal history: within a relationship; gender of partner; self-rated quality of relationship measure.
¢ Disease information: cancer diagnosis (cervix, ovarian, endometrial, other), stage of disease at
diagnosis, time since end of primary treatment in months, stage of disease at last appointment
(relapse or first-line treatment), treatment modality.
¢ Eastern Co-operative Oncology Group/World Health Organization: performance status (0–5)
assessed by clinician, for which 0 = fully active and able to carry on all pre-disease performance
without restriction and 5 = dead.70
All cancer disease information was to be gathered by the RA on each site from electronic records and
cross-checked against the hospital database on all gynaelogical oncology patients (Table 1).
TABLE 1 Measures and time points of administration
Name of outcome measure
Time point
Baseline (T1) 4 weeks (T2) 10 weeks (T3) 25 weeks (T4) 8 months (T5)
Demographics, personal history ✗
Diagnosis, stage, treatment ✗
FSFI ✗ ✗ ✗
SQOL ✗ ✗ ✗ ✗ ✗
EQ-5D-5L ✗ ✗ ✗ ✗ ✗
CSRI – to cover use of services in
the previous . . .
✗ 3 months ✗ 6 months ✗ 2 months
PHQ-9 ✗ ✗ ✗ ✗ ✗
GAD-7 ✗ ✗ ✗ ✗ ✗
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Description and justification of the duration of treatment, subject participation and trial
follow-up
Outcome measure collection time points were set independent of the intervention delivery to ensure
standardised collection of data and consistency between the intervention group and controls:
l T1 – baseline assessment and level 1 booklet given.
l T2 – 4 weeks (to allow use of the booklet and reassessment).
l T3 – 10 weeks from baseline. All women in intervention group should have completed level 2 by this
time. Two to five fortnightly sessions. Length of treatment derived from existing manual and evidence.
l T4 – 25 weeks from baseline (primary end point).
l T5 – Follow-up data collected 8 months after baseline (follow-up).
The willingness of women to participate at each level was to be measured by counting the uptake of each
intervention when offered and attendance at sessions offered. Their preference for any particular therapy
was to be measured at baseline with the preference for treatment measure.
Trial follow-up was planned to be 8 months from baseline to evaluate whether or not any advantage of
treatment endured over time, and to allow for, and to compare against, natural recovery rates in the
ETAU group.
The follow-up time of 8 months, as opposed to 12 months as originally planned in the protocol submitted
to NIHR, was proposed by the TSC when it first met the project team in August 2015. It was suggested
that this would be a meaningful follow-up period while extending the time period available to recruit
participants who could (theoretically) progress sequentially through all three interventions within the time
period of the study. Unfortunately, this was not discussed with the funders at the time and was held to be
a breach of contract as well as being considered an inappropriately short follow-up period.
Qualitative investigation
Semistructured interviews were to be conducted at 9 months with a purposive sample of 18 patients
randomised to the stepped care arm of the trial to explore their experience of the process of recruitment
to the trial and of receiving the interventions. Good and poor responders were to be chosen, as were
those who did not take up the offer of interventions. Women were to be asked about their experience
of the ‘stepped care‘ model, and whether or not they liked the interventions that were offered to them.
Women who dropped out or withdrew were to be asked for their reasons at point of leaving (if women
had previously consented to do this at randomisation). We also intended to interview clinical staff to
understand their experiences of recruiting participants to the trial, and senior clinicians and managers
about the operation of the SAFFRON intervention and stepped care model. These data were to be
analysed thematically using the framework approach71,72 with the aid of QSR NVivo qualitative data
analysis software (QSR International, Warrington, UK) to provide important information on acceptability
and potential for harm, as well as potential obstacles to and facilitating elements of the intervention.
At follow-up, the RA was to establish and record any additional treatments or information women had
accessed, and record timing of drop-out from treatment or follow-up and reasons for drop-out, when
ascertainable. They could telephone the women, e-mail them (with permission from women if given in the
initial consent form) or visit them in their homes if they were too ill or fatigued to attend clinic.
Analysis
Statistical plan
The aim of the study was to establish the feasibility of a larger trial of the proposed stepped care
intervention.
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The critical parameters that were to be used to quantitatively assess feasibility were the:
l consent rate
l proportion in the intervention group who moved up at least one step on the intervention
l proportion of all randomised subjects who had a useable (non-missing) score for total FSFI (the proposed
primary outcome for any subsequent study) at 8 months.
To inform whether or not a main trial might be viable, the study planned to examine whether or not it is
possible to achieve:
l a consent rate of ≥ 40%
l ≥ 70% of randomised subjects having a useable (non-missing) score for total FSFI (our primary
outcome) at 8-month follow-up.
We also intended to use the feasibility data to provide an estimate of standard deviation of the FSFI score
that would be required for the sample size calculation of the main trial.
A sample size of 100 patients, randomised equally to the two treatment groups, was chosen for this
feasibility work. This sample size is shown below to be adequate to ensure sufficient precision to exclude
the minimum acceptable values for the three critical parameters based on exact, one-sided 95% confidence
intervals around assumed values for each parameter:
l Consent rate. We expected that 50% of women would consent to randomisation. With a sample size
of 100 women, this consent rate could have been estimated with a lower 95% confidence interval
of 44%.
l Proportion in the intervention group who move up at least one step on the intervention. We expected
that 80% of the 50 women allocated to the intervention group would step up at least one level on
the intervention during their treatment period. We planned to estimate our expected proportion of
80% with a lower 95% confidence bound of 68%.
l Proportion of all randomised subjects who had a useable score for total FSFI at 8 months. We estimated
that 80% of the 100 women randomised in the trial would provide useable data to score the FSFI at
8 months. With 100 women we would have been able to estimate 80% with a lower 95% confidence
bound of 72%.
Data from 100 patients would also be adequate to provide a precise estimate of the standard deviation of
the primary outcome (FSFI) score to inform the sample size calculation for the main trial.73
Economic evaluation plan
The aim of the economic evaluation was to optimise the methods of conducting an economic evaluation
of the stepped care system compared with ETAU as part of a full trial. This would have included an
estimate of the cost of stepped care and an evaluation of using a gynaelogical oncology-specific version
of the CSRI to collect resource use data. A preliminary cost–utility analysis would have been conducted,
reporting the incremental cost per QALY gained of the stepped care system compared with ETAU.
The key aim of this would have been to evaluate the effect of using the EQ-5D-5L to calculate QALYs
in this patient group versus a sexual function measure (the SQOL questionnaire) to calculate QALYs.
Recruitment rate required by the study
We aimed to recruit two or three women per week for 9 months between both sites.
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Changes to methods before planned study commencement
1. The REC review changed the original study design. Concerns about women in the control arm being
identified as having clinically significant sexual difficulties, and the awareness that there is no consistently
available TAU for this, led the REC to ask for the level 1 booklet to be given to participants in both arms
of the study. This point had been raised by patient advocates during the intervention development and
was accepted by the research team.
2. When the TSC was convened in August 2015, its members were concerned that the full study would not
be achievable with 1 full year of follow-up. The research team had hoped that there could be a no-cost
extension to the study but this was not possible. To make the study more achievable, they proposed
(1) reducing the follow-up period to 8 months and (2) introducing the SQOL as a within-treatment
measure allowing the FSFI to be the outcome measure for sexual function. This required a substantial
amendment and resubmission to the REC and engendered further delay. Convening the TSC earlier
would have helped mitigate this delay.
Results
Closure of study
The study was closed by the funder, NIHR, in November 2015 because of slow progression to recruitment
as well as changes to the protocol made after its original filing with NIHR, which led to a substantial REC
amendment. There are, therefore, no results of the stepped care intervention with patients and the
questions posed in the objectives cannot be answered here.
Set-up and site opening delay
Administrative delay in the legal and financial set-up of the study, and hence funding of access to clinicians‘
time to contribute to the intervention development, posed severe challenges to the timely progress of the
study in the first instance. The set-up of the study was hindered by the chief investigator (CI) being a clinician
without previous experience of running a trial. Administrative support from within the NHS was a secondment
from an inexperienced, albeit enthusiastic, staff member who was unaware of mechanisms to raise the profile
of the study locally within the local bureaucracy.
Working across a range of hospitals and a university proved difficult for set-up, and some hospitals asked
to release a clinical staff member to write the intervention. Professor Alessandra Lemma had never undertaken
such a financial or legal arrangement before. It seemed very clear that setting up a psychosocial study within
a medical setting was very complex and unfamiliar to those who were highly competent at setting up a
drug study.
The development of the interventions took substantially longer than the time estimated in the application.
The lack of prepared interventions had been signalled as a risk by one reviewer in response to the original
response to the commissioned call from the HTA programme.
The study was initially suspended by NIHR in October 2014 for financial reasons, with the assumption that it
would be at least 1 year before it was restarted, and many involved assumed that it was permanently halted.
Momentum was lost at this point, which was, in retrospect, key. Once funding restarted in February 2015,
it was problematic to re-engage clinicians and the services, as they had made plans that excluded the study.
Employment processes within the university for RAs needed to be started from scratch.
Once the interventions were ready and the study was able to progress, nursing teams felt unable to participate
as trainees and deliverers of a new psychoeducational intervention, causing the need to seek other staff to
deliver level 2. This was because of maternity leave at one site, a prospective hospital merger at the other and
the need to have two CNSs at each site, one study trained and the other not. By contrast, clinical psychologists
at both sites were fully trained in the level 3 intervention and were piloting it without difficulty. They were
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unconcerned about delivering the level 3 intervention, largely because it offered new resources in terms of
skills, and the intervention fell within the professional demands of their role.
A substantial ethics amendment was required after the meeting of the TSC in August 2015, in which the
committee recommended the addition of two further measures and, in addition, suggested that in order
to keep the study within its time limits, the follow-up period should be shortened. All three changes
formed part of the amendment.
There were differences between the two sites with respect to trust research and development approval.
One was flexible and responsive. The other had still not approved research and development at the point
of the study closure despite the application being over 2 months in the system.
Achievements of study and responses to obstacles
This section describes that which was completed and changes that occurred in the pre-recruitment phase
to address obstacles that arose.
The development of the stepped intervention was completed. The study adapted to input from the REC
that asked it to change the TAU arm to give participating women a better clinical experience.
Training of CNSs (as originally envisaged) at both sites was delayed by issues of:
l maternity leave of one study CNS, with locum cover inappropriate for the study in terms of both
training and in length of contract
l lack of funding for backfill of CNS time while delivering level 2 intervention
l work demands at one site changing substantially after the project commenced because of a projected
merger of hospitals within the time frame of the study.
Teams in both sites were keen that the study should proceed but neither team of CNSs was able, at the
time the study went live, to offer CNSs for training and participation. The study therefore approached
supernumerary staff at each site to train in, and deliver, the level 2 intervention. At UCLH this staff
member was a former nurse consultant, currently running the UCLH Cancer Centre Macmillan Support
and Information Service, and at University Hospitals Bristol the staff member was a consultant specialist
radiographer who had academic time in her job plan that enabled her to participate.
Training
Initial training of level 2 therapists for Bristol and UCLH was written and delivered using a Microsoft
PowerPoint® (Microsoft Corporation, Redmond, WA, USA) summary of the background of the study
[see section 4 PDF; URL: www.journalslibrary.nihr.ac.uk/programmes/hta/1111102/#/ (accessed December
2018)], and by working through each of the required sessions. Teaching involved some didactic elements
and substantial role play and group discussions. Although highly experienced in general counselling
techniques, feedback from both therapists revealed that they were not yet confident about carrying out
specific psychological techniques, such as taking a behavioural history, or ‘gently challenging beliefs‘ as
required in one session. It appeared that each session required about 3 hours‘ teaching time. At the point
the study was halted, both had requested, in addition to supervision on pilot cases, top-up training. This
was arranged but could not occur as the study was halted. This suggests that cross-disciplinary training
with psychological interventions requires more time than was envisaged in this study.
Training of three clinical psychologists in IPT-GO was delivered by Professor Lemma in a full day. This used
the national IPT training as its foundation, and additional material was included to show how IPT-GO differed
from usual IPT for depression. All three psychologists felt confident to deliver IPT-GO and initial pilot cases
completed before formal opening of recruitment. Professor Lemma judged them capable of carrying out
IPT-GO within the confines of the study (i.e. with follow-up supervision on the first cases). The difference in
confidence and capacity may derive from the fact that Professor Lemma is highly experienced in training
for IPT. It may also be related to the fact that clinical psychologists are, by definition, used to delivering a
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range of different therapies. Although newly formulated, IPT-GO was closely related to their core skills and
discipline, and they were able to develop quickly variations on their technique as required.
Other outcomes
Preparation of the full range of study documents was completed [see Section 2, 3 and 4 PDFs;
URL: www.journalslibrary.nihr.ac.uk/programmes/hta/1111102/#/ (accessed December 2018)].
Interview schedules for the qualitative study were prepared (see Appendices 10 and 11).
All intervention documents are archived at UCL. Level 1 contains elements derived from a document for
which the American Cancer Society holds copyright, and these are unable to be reproduced in any form
outside the study, including in this report and online.
Level 2 manual and worksheets can be obtained from either Dr Sue Gessler or Dr Lori Brotto on application
for use by qualified psychologists in the setting of a study (this permission level is set by Dr Lori Brotto as the
copyright holder).
Level 3 is incompletely developed and has not been tested in a study. Following opinions of the TSC
and the project team, on ethical and intellectual property grounds, it is not available outside the prospect
of an IPT training setting and a prospective study for its use in the gynaelogical oncology setting by
appropriately trained individuals. Any such approach should be made to Dr Gessler or Professor Lemma.
Access requires IPT-qualified clinicians with a capacity to train in its application to gynaelogical oncology
and a prospective study to complete the appropriate development stages for a new psychological therapy.
Learning for the future
Closure of the study was regretted by the clinical teams at both project sites as they had welcomed the
prospect of new interventions for their patients. The TSC considered the interventions to be worthwhile
and well developed.
Causes of delay
Development of the intervention took substantially longer than initially envisaged. The research team
delayed key parts of the study in the attempt to get the interventions right. In particular it was important to
acknowledge the patient input, which changed the team‘s initial assumptions, in particular interpretation
of the commissioned call as attending to mood. Major input adapting mental health materials on mood in
the stepped intervention was found pathologising and inappropriate by the patient advocates. The project
team found this highly valuable, leading to a more robust and patient-appropriate set of interventions. The
research team considered that it was better to delay while getting the interventions right, drawing on wide
experience in psychological intervention research. However, these changes led to delays in advertising for
RAs and in progress, which contributed to the initial suspension of the study.
The structure of the intervention itself changed during this time. The original design envisaged direct access
via the treatment algorithm to levels 2 and 3, as successfully used in IAPT. The REC was concerned for the
well-being of women in the control arm, in that they had been identified as being in need of, and wanting,
help for sexual difficulties and would be offered nothing. They asked whether we could offer both arms
the level 1 booklet, changing the TAU arm to an ETAU arm. This change in design had the advantage of
dealing with any prospective contamination between arms by widespread distribution of the booklet within
clinics. It also addressed a concern of the patient advocates, who had pointed out as the interventions were
developed that much of the level 1 and level 2 materials were unknown to them, and would be a necessary
basis for any more psychologically intense intervention. The learning from this element was that mapping
directly from psycho-oncology to mainstream clinical psychology interventions is often perceived as unhelpful
by both patients and RECs, and such differences should be considered at an early stage.
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Administrative delay in the legal and financial set-up of the study, and hence funding of access to
clinicians‘ time to contribute to the intervention development, posed severe challenges to the timely
progress of the study. This appeared to be rooted in institutional barriers to setting up a psychosocial study
in cancer services within the NHS; for example, some involved institutions had never participated in this
way before and did not understand the processes involved or required. Formal structures between the NHS
division and UCL did not work as well as would be expected. Many processes had to be repeated across
organisations. The release of clinical time by a full-time clinician to develop the level 3 intervention (AL)
required advance agreement, which led to further delay.
Major issues arose as a result of the intention to conduct the trial within the existing clinical teams,
including using clinical staff to deliver the interventions. This intention was in line with the recommendation
of the 2009 Cochrane review29 aimed at speeding subsequent integration into clinical practice. However,
implementation of the study was therefore subject to real-life fluctuations in staff and in the clinical
demands on teams the trial necessarily involved.
The study had proposed one CNS to be trained and the other to offer TAU at each site. At one site, the
maternity leave of the CNS intended to be trained for the study, together with delays and concerns about
locum cover, left the site without a CNS to be trained, and the lead CNS was no longer able to support
the study. At the second site, despite initial enthusiasm, at the point of training, the CNS team was unable
to offer a staff member, owing to concerns about existing clinical load and a prospective enlargement of their
catchment area with a consonant rise in referrals to the centre. Hence searches were made for alternative
staff with links to the clinical teams but who were able, owing to the structure of their jobs, to take on an
extra task both of training and of clinical input. Although ultimately successful, this also led to delay.
The nursing teams at both sites stated that they were under clinical pressure, and the inability of the study
to offer direct backfill for their time was a further obstacle. The original proposal to the HTA programme
for this study proposed a trial CNS for 18 months with clerical support to address issues of clinical demand
on existing teams, and to examine the effect of the intervention as delivered by CNSs. The team was
advised that under the terms of a HTA award, this could not be funded as it would appear as a NHS excess
treatment cost. Although the CI secured limited charitable funding to support the CNS teams, terms of the
charity prevented direct payment for staff time, and hence this did not fully allay the concerns of the nursing
teams. Other psychosocial studies funded differently have tended to establish the intervention with research
staff initially, and then proceed with the roll-out into clinical practice. With hindsight, this might have been
a preferable approach to the development and testing of the SAFFRON interventions.
Attempting to launch in both sites simultaneously added delay. A pilot phase at UCLH before moving to
Bristol could have given opportunities for ironing out logistical issues and service delivery problems.
Positive outcomes
Patient involvement was present from the inception of the study, contributing at all points and forming a
particularly valuable part of the study process for all the participating clinicians and academics.
The interventions are now adapted for the UK and for the gynaelogical oncology patient group. A subsequent
study may be able to establish whether or not they are effective as an intervention over TAU. They are
available through contact with the CI, subject to copyright agreements.
The development of the interventions and the discussion at the two sites has raised the profile of
psychosexual difficulties after gynaecological cancer within both centres and the need for patients to be
asked about their psychosexual well-being in follow-up clinics. It is not known if this has led to any change
in practice.
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Conclusions and recommendations for further research
Given the stated views of the TSC, the patient advocates on the project and the clinical teams at both
sites, the SAFFRON interventions appeared appropriate for managing sexual difficulties after treatment for
gynaecological cancer. These interventions should be tested within a formal research study in the future.
Delivery of these interventions within and in parallel to usual care would require careful planning and
resource and time allocation.
This study showed that it was not feasible to deliver the SAFFRON stepped care approach within the
structure of the trial and with the resources available within the usual clinical setting. Given the difficulties
of maintaining continuity of staff within busy clinical settings, it would be helpful if the designated
deliverers of new face-to-face interventions were formally research funded, and were supernumerary to
the existing clinical team.
It is essential that any further study in this area continues to have strong patient involvement in the model
of that which has formed a key part of SAFFRON.
The experience of the team showed that, other than institutional delays, there were two main problems
with the study itself:
1. slowness in finalising the intervention and accompanying materials
2. finding staff with the time and commitment to deliver the interventions.
This suggests that future research should explicitly focus on the intervention development phase. SAFFRON
attempted to design an intervention and test it in a feasibility trial in two separate clinical settings. It was a
complex intervention requiring a range of changes within an existing clinical system, and future studies
should follow the Medical Research Council‘s complex intervention guidance.74 This means moving away
from using the model of phases of drug development and separating out intervention development
from implementation.
Interventions should be evidence and theory based and well formulated before proceeding to a full trial.
Such processes tend to allow grassroots service providers to be fully involved in the development process
and hence better skilled and more motivated to deliver the interventions.
This could lead to difficulties in providing that ‘clear water‘ between two groups in a RCT, but different
trial designs can be used to accommodate such difficulties. A cluster trial, in which one whole service
delivers the intervention to everyone and one whole service delivers usual care, would be one way of
working within a single clinical service to bring about change, rather than attempting to randomise two
groups within one service, with its attendant problems of contamination.
Implementation studies should occur in advance of a full trial to cost the intervention and iron out any
implementation barriers. These should take account of the range of factors involved in improving health
care. Ferlie and Shortell75 conceive of four levels of change: individual, group or team, organisation and the
environment in which the organisation is embedded. They suggest that, to maximise chances of successful
change, all four levels must be considered.
Grol et al.76 point out the need to recognise the interaction between an intervention and the complex
setting in which it is used, and suggest the need for a process theory to cover both the ‘organisational
plan‘ and the ‘utilisation plan‘. This would include working closely with the target group (in this case,
doctors, nurses and psychologists working in gynaelogical oncology clinics) and involving them in the
development of the innovation and the implementation plan.
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A sequential approach to implementation would require, before proceeding to a full trial, an implementation
study with analysis of reasons for departure from the desired change, looking at characteristics of the target
group and setting, influential individuals and factors that promote, or inhibit, the change. Interventions
regarding sexuality can be particularly sensitive to resistance at professional and patient levels, so even more
development may be required.
Stepped care as a model is itself sophisticated and was similarly examined in its implementation phase
within mental health in routine care.49
The main trial questions of efficacy or effectiveness remain to be answered in any future study, but the
current study focused on feasibility. Our conclusions are that it was not feasible to deliver our stepped care
approach within the structure of the trial and the resources (mainly clinical researchers) that were available.
The areas to be worked on in future studies should focus on acceptability, involvement and structures.
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Appendix 1 Female Sexual Function Inventory
Reproduced with permission from Jules Mitchel, Target Health Inc., January 2018.
Female Sexual Function Index (FSFI) © 
Study ID ……………………………………. Date …………………………….
Instrucons: 
These quesons ask about your sexual feelings and responses during the past 4 weeks.
Please answer the following quest ions as honestly and clearly as possible. Your responses 
will be kept completely confident ial. In answering these questions the following deﬁnions 
apply:
Sexual act ivity can include caressing, foreplay, masturbat ion and vaginal intercourse.
Sexual intercourse is def ined as penile penetrat ion (entry) of the vagina. 
Sexual st imulat ion includes situat ions like foreplay with a partner, self-st imulat ion 
(masturbaon), or sexual fantasy.
Tick only one box per queson
Sexual desire or interest is a feeling that includes want ing to have a sexual experience, 
feeling recept ive to a partner's sexual init iat ion, and thinking or fantasizing about having
sex.
1. Over the past 4 weeks, how oen did you feel sexual desire or interest? Almost always
or always
Almost always or always
Most t imes (more than half the t ime) 
Somet imes (about half the t ime) 
A few t imes (less than half the t ime) 
Almost never or never
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Very low or none at all 
Sexual arousal is a feeling that includes both physical and mental aspects of sexual 
excitement. It may include feelings of warmth or t ingling in the genitals, lubricat ion 
(wetness), or muscle contract ions. 
3. Over the past 4 weeks, how would you rate your level (degree) of sexual desire or 
interest? 
 No sexual act ivity 
 Almost always or always 
 Most t imes (more than half the t ime) 
 Somemes (about half the t ime) 
 A few t imes (less than half the t ime) 
 Almost never or never 
4. Over the past 4 weeks how would you rate your level of sexual arousal (“turn on”) 
during sexual act ivity or intercourse 
 No sexual acvity 




 Very low or none at all 
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5. Over the past 4 weeks how conf ident were you about becoming sexually aroused during
sexual act ivity or intercourse?
No sexual act ivity 




Very low or no conf idence 
6. Over the past 4 weeks, how oen have you been sat isf ied with your arousal
(excitement) during sexual act ivity or intercourse? 
No sexual act ivity 
Almost always or always
Most t imes (more than half the t ime) 
Somemes (about half the t ime) 
A few t imes (less than half the t ime) 
Almost never or never
7. Over the past 4 weeks, how oen did you become lubricated (“wet”) during sexual 
act ivity or intercourse?
No sexual act ivity 
Almost always or always
Most t imes (more than half the t ime) 
Somet imes (about half the t ime) 
A few t imes (less than half the t ime) 
Almost never or never
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8. Over the past 4 weeks, how dif f icult was it to become lubricated (“wet”) during sexual 
act ivity or intercourse? 
 No sexual act ivity 
 Extremely dif f icult or impossible 
 Very dif f icult 
 Dif f icult
 Slightly dif f icult 
 Not dif f icult 
9. Over the past 4 weeks, how of ten did you maintain your lubricat ion (“wetness”) unt il
compleon of sexual act ivity or intercourse? 
 No sexual act ivity 
 Almost always or always 
 Most t imes (more than half the t ime) 
 Somet imes (about half the t ime) 
 A few t imes (less than half the t ime) 
 Almost never or never 
10. Over the past 4 weeks, how dif f icult was it to maintain your lubricaon (“wetness) unt il 
compleon of sexual act ivity or intercourse? 
No sexual act ivity 
Extremely dif f icult or impossible 
Very dif f icult 
Dif f icult
Slightly dif f icult 
Not dif f icult 
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11. Over the past 4 weeks, when you had sexual st imulat ion or intercourse, how oen did 
you reach orgasm (climax)? 
No sexual act ivity
Almost always or always
Most t imes (more than half the t ime) 
Somet imes (about half the t ime) 
A few t imes (less than half the t ime) 
Almost never or never
12. Over the past 4 weeks, when you had sexual st imulat ion or intercourse how dif f icult was 
it for you to reach orgasm (climax)? 
No sexual act ivity 
Extremely dif f icult or impossible 
Very dif f icult 
Dif f icult 
Slightly dif f icult 
Not dif f icult 
13. Over the past 4 weeks, how sat isf ied were you with your ability to reach orgasm (climax)
during sexual act ivity or intercourse?
No sexual act ivity 
Very sat isf ied
Moderately sat isf ied
About equally sat isf ied and dissat isf ied 
Moderately dissat isf ied
Very dissat isf ied
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14. Over the past 4 weeks, how sat isf ied have you been with the amount of emot ional 
closeness during sexual act ivity between you and your partner?
No sexual act ivity 
Very sat isf ied
Moderately sat isf ied
About equally sat isf ied and dissat isf ied 
Moderately dissat isf ied
Very dissat isf ied
15. Over the past 4 weeks, how sat isf ied have you been with your sexual relat ionship with
your partner?
Very sat isf ied
Moderately sat isf ied
About equally sat isf ied and dissat isf ied 
Moderately dissat isf ied
Very dissat isf ied
16. Over the past 4 weeks, how sat isf ied have you been with your overall sexual life?
Very sat isf ied
Moderately sat isf ied
About equally sat isf ied and dissat isf ied 
Moderately dissat isf ied
Very dissat isf ied
APPENDIX 1
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17. Over the past 4 weeks, how oen did you experience discomfort or pain during vaginal 
penetration? 
 Did not attempt intercourse 
 Almost always or always 
 Most t imes (more than half the t ime) 
 Somet imes (about half the t ime) 
 A few t imes (less than half the t ime) 
 Almost never or never 
18. Over the past 4 weeks, how oen did you experience discomfort or pain following 
vaginal penetrat ion? 
 Did not attempt intercourse 
 Almost always or always 
 Most t imes (more than half the t ime) 
 Somet imes (about half the t ime) 
 A few t imes (less than half the t ime) 
 Almost never or never 
19. Over the past 4 weeks, how would you rate your level (degree) of discomfort or pain 
during or following vaginal penetrat ion? 





Very low or none at all 
Thank you for complet ing this quesonnaire 
Copyright ©2000 All Rights Reserved 
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Appendix 2 Generalised Anxiety Disorder
Questionnaire
Generalised Anxiety Disorder Questionnaire 
(GAD-7)
Study ID ……………………………….. Date …………………………….
Instructions: These questions ask about how you have been feeling in the last 2 week s. Your
responses will be kept completely confidential.
Tick only one box per question
Over the last 2 weeks, how often have you been bothered by any of the following
problems?
Thank you for completing this questionnaire 
1. Feeling nervous, anxious or on edge
2. Not being able to stop or control worrying
3. Worrying too much about different things
4. Trouble relaxing
5. Being so restless that it is hard to sit still
6. Becoming easily annoyed or irritable
7. Feeling afraid as if something awful might
happen
 Total Score………………… = .............+ ............. + ............. + .............
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Appendix 3 Patient Health Questionnaire
Patient Health Questionnaire – PHQ-9 
Study ID: …………………….      Today’s Date: …………………...
Fill in the boxes with pen or pencil to mark your answers.












1. Lile interest or pleasure in doing things
2. Feeling down, depressed or hopeless
3. Trouble falling/staying asleep, sleeping too much
4. Feeling red or having lile energy
5. Poor appete or overeang
6. Feeling bad about yourself – or that you are a failure 
or have let yourself or your family down
7. Trouble concentrating on things such as reading the 
newspaper or watching television
8. Moving or speaking so slowly that other people
could have noced.  Or the opposite – being so
ﬁdgety or restless that you have been moving
around a lot more than usual 
9. Thoughts that you would be beer off dead or of
hurting yourself in some way 
Total Score…………………  .........+ .........+ .........+ .........+
B. If you have been bothered by any of the 9 problems listed above, please answer the 
following: 
How diﬃcult have these problems made it for you to do your work, take care of things
at home, or get along with other people?
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Appendix 4 EuroQol-5 Dimensions,
five-level version




UK (English) © 2009 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
Health Questionnaire
English version for the UK
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UK (English) © 2009 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
Under each heading, please tick the ONE box that best describes your health TODAY.
MOBILITY
I have no problems in walking about
I have slight problems in walking about
I have moderate problems in walking about
I have severe problems in walking about
I am unable to walk about
SELF-CARE
I have no problems washing or dressing myself
I have slight problems washing or dressing myself
I have moderate problems washing or dressing myself
I have severe problems washing or dressing myself
I am unable to wash or dress myself
USUAL ACTIVITIES (e.g. work, study, housework, family or
leisure activities)
I have no problems doing my usual activities
I have slight problems doing my usual activities
I have moderate problems doing my usual activities
I have severe problems doing my usual activities
I am unable to do my usual activities
PAIN / DISCOMFORT
I have no pain or discomfort
I have slight pain or discomfort
I have moderate pain or discomfort
I have severe pain or discomfort
I have extreme pain or discomfort
ANXIETY / DEPRESSION
I am not anxious or depressed
I am slightly anxious or depressed
I am moderately anxious or depressed
I am severely anxious or depressed
I am extremely anxious or depressed
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UK (English) © 2009 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
The worst health 
you can imagine
• We would like to know how good or bad your health is TODAY.
• This scale is numbered from 0 to 100.
• 100 means the best health you can imagine.
0 means the worst health you can imagine.
• Mark an X on the scale to indicate how your health is TODAY.
• Now, please write the number you marked on the scale in the box 
below.
The best health 
you can imagine






















DOI: 10.3310/hta23060 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 6
UK (English) © 2009 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
49

Appendix 5 Sexual Quality of Life
Sexual Quality of Life: female questionnaire
Sexual Quality of Life cannot be reproduced in a document but can be accessed freely at
www.pfizerpatientreportedoutcomes.com.77
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Appendix 6 Client Service Receipt
Inventory – Short
Adapted from Beecham and Knapp.69 Materials below contain material from www.nhs.uk/Conditions/
stress-anxiety-depression/Pages/Types-of-therapy.aspx (accessed 10 January 2018) © Crown copyright
2018. Contains public sector information licensed under the Open Government Licence v3.0.
Client Service Receipt Inventory (CSRI) – Short 
Study ID No: ……………………………..              




Inpaent stay (1) state reason: 
……………………………………………………….…
Yes No days
Inpaent stay (2) state reason: 
……………………………………………………………
Yes No days
GP Yes No contacts
Psychiatrist Yes No contacts
Hospital Doctor for your physical health (1) 
Specify ………………………………………………..
Yes No contacts
Other doctor (2) 
Specify ………………………………………………..
Yes No contacts
Accident and emergency Yes No visits
Primary care nurse Yes No contacts
Nurse for your physical health Yes No contacts
Psychologist/Counsellor or Talking Therapist Yes No contacts
‘Complementary’ medicine or therapy specify Yes No contacts
Occupaonal Therapist, Physiotherapist or Speech 
Therapist
Yes No contacts
Service Circle Number 
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2. How many days have you lost from work in the last 6 months as a result of illness 
(insert zero if not applicable)?
3. How many days have you lost from school/college/university in the last 6 months as 
a result of illness (insert zero if not applicable)?
……………… days
4. Date Completed: …………………………………………………………..
……………… days
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Health Care Resource Use – SAFFRON – 8 month data collection (T5) 
These questions relate to your use of health and social care resources in the last 2 months. Please 
answer as accurately as possible. If you are unsure of which types of therapy you have received, we 
have provided some information to help on the final page of this questionnaire. If you have any 
further questions, please ask the researchers. 
Secon 1: Community-based care (NHS and private)
In the last 2 months, have you used any community-
based care face to face, or by telephone?
Yes 1
Please give more 
details below
No 0 
Please skip ahead to
Medication section




Cost per session/visit/ 
transportaon (if not 
NHS) 
GP appointment 
(in the surgery) – NHS 
Yes 1 No 0
GP appointment 
(by phone) – NHS 
Yes 1 No 0
Practice nurse appointment 
(in the surgery) – NHS 
Yes 1 No 0
Practice nurse appointment 
(by phone) – NHS 
Yes 1 No 0
Outpatient hospital appointment –
NHS 
Yes 1 No 0
What was the main reason for the appointment(s)?
..........................................................................................
And who did you see for this reason (i.e. 
what type of health care professional)?
……………………………………….
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Counselling (or talking therapy/ 
mindfulness) – NHS 
Yes 1    No 0
Counselling (or talking therapy/ 
mindfulness) – Private 
Yes 1    No 0
£       :           
[write “INS” if covered by
private health insurance]
Face-to-face cognive behavioural
therapy (CBT) – NHS 
Yes 1    No 0
Face-to-face cognive behavioural
therapy (CBT) – Private 
Yes 1    No 0
£       :           
[write “INS” if covered by
private health insurance]
APPENDIX 6





Cost per session/  
visit/transportaon 
(if not NHS) 
Computer-based (online) cognitive  
behavioural therapy (CBT) – NHS
Yes 1 No 0
Psychotherapy – NHS Yes 1    No 0
Sex therapy – NHS Yes 1    No 0
Complementary medicine or 
therapy – NHS 
Yes 1 No 0
Please specify
…………………………………………………………………………………………….
Complementary medicine or 
therapy – Private
Yes 1 No 0
£       :           






Physiotherapist or Speech Therapist
– NHS 
Yes 1 No 0
Occupational Therapist, 
Physiotherapist or Speech Therapist
– Private
Yes 1 No 0
£       :           
[write “INS” if covered 
by private health
insurance]
NHS Direct or “Call 111” Yes 1    No 0
NHS walk-in centres Yes 1    No 0
Other drop-in centres, e.g. 
Macmillan/Maggie’s
Yes 1    No 0
Ambulance or hospital transport –
NHS 
Yes 1    No 0
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Other (please specify) – NHS 
.........................................................
......................................................... 
Yes 1    No 0
Other (please specify) – Private 
.........................................................
......................................................... 
Yes 1    No 0
£       :           
[write “INS” if covered by
private health insurance]
Section 2: Medication
Have you been prescribed any medications to help your 





Please skip ahead to
Other care section





(e.g. twice a day)
Date first 
prescribed
Number of days at 
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Section 3: Other care
In the last 2 months, apart from the care described above, 
have you received any other care provided by the NHS,
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Further Information on Different Types of Therapy
Counselling/ Talking Therapy
Having counselling is probably the best-known talking therapy and the one most readily available at your
GP surgery. Counselling on the NHS usually consists of 6 to 12 sessions, each an hour long. You talk in
conﬁdence to a counsellor about how you feel about yourself and your situaon. The counsellor supports 
you and oﬀers praccal advice.
Cognitive Behavioural Therapy (CBT)
The aim of CBT is help you think less negavely, so that instead of feeling hopeless and depressed, you 
cope beer with and even start to enjoy the situaons you face. In CBT, you set goals with your therapist 
and carry out tasks between sessions. A course typically involves around six to 15 sessions, which last 
about an hour each. Like counselling, CBT deals with current situaons more than events in your past or
childhood. 
Psychotherapy
Unlike counselling and CBT, psychotherapy involves talking more about your past to help you overcome 
problems you’re having in the present. It tends to last longer than CBT and counselling. Sessions are an
hour long and can connue for a year or more. There are diﬀerent types of psychotherapy, but they all 
aim to help you understand more about yourself, improve your relaonships and get more out of life.
Psychotherapy can be especially useful in helping people with long-term or recurring problems to ﬁnd the 
cause of their diﬃcules. NHS psychotherapists normally work in a hospital or clinic, where you'll see them
as an outpaent. Private psychotherapists often work from home. 
Sex Therapy 
A sex therapist will listen to you describe your sexual problems and assess whether the cause is likely to 
be psychological, physical or a combinaon of the two.The aim of talking about and exploring your
experiences is to help you get a beer understanding of what is happening and the reasons. The therapist 
may also give you exercises and tasks to do with your partner in your own me. 
You can see a sex therapist by yourself, but if your problem aﬀects your partner as well, you may both 
aend. Sessions usually last for 30-50 minutes. The therapist may advise you to have weekly sessions or to
see them less frequently, such as once a month.
Complementary Medicine/ Therapy 
These medicines and treatments range from acupuncture and homeopathy to aromatherapy and
meditaon. Treatments are somemes used to provide an experience that is pleasant in itself. This can 
include use alongside convenonal treatments, to help a paent cope with a health condion. When used 
this way, the treatment is not intended as an alternative to convenonal treatment.
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Appendix 7 Preference measure
Preference Measure 
_________________________________________________________________________
|                        | |                       | |                        |   | 
DOI: 10.3310/hta23060 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 6
© Queen‘s Printer and Controller of HMSO 2019. This work was produced by Gessler et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
61

Appendix 8 Reasons for withdrawal
Reasons for Withdrawal
Study ID: ………………………………….. Date: …………………………………………
Please tick any of the below that led you to decide to withdraw from the study. By providing 
this information you will be helping in the design of future studies. 
It is important you answer the questions carefully and accurately. There are no right or wrong 
answers to these questions, and your responses will in no way affect your routine care. 
The reasons for your withdrawal will be entirely anonymous and confidential. You may not
decide to give this information. 
Reason for Withdrawal Yes No Maybe Details 
Interventions were not appropriate/ suitable for 
my situation 
Which level of intervention did you feel was not appropriate
or suitable?
         1 = Self help booklet 
         2 = Psychoeducation (with CNS or radiographer)
         3 = Interpersonal therapy (with psychologist) 
I was unhappy with the group that I was  
randomly assigned to and would have preferred 
to be in the alternative group
The design of the study was too difficult to
understand
Participation was inconvenient to everyday life
There were side effects of the study 
I did not feel well enough to continue on with
the study
Trials are not appropriate in serious illness 
The treatment does not offer the best option
The trial had no personal benefits 
I prefer other means of treatment
The trial took up too much time  
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Reason for Withdrawal Yes No Maybe Details 
The trial was not what I expected it to be/ the 
information I received at the beginning was 
inadequate
Transport or distance to hospital/ trial site 
I did not have enough family support 
I felt very anxious 
I felt uncomfortable with experimentation 
I felt I was not in control of decision-making 
I felt uncertain 
I thought my quality of life was reduced as a 
result of participation 
I fear or mistrust the researchers
I feel the relationship with my treatment team
(e.g. doctors/ nurses etc.) was effected 
I believe my doctor should be making the 
decisions
I felt coerced to join
I did not feel well enough to continue
I was already involved in another trial 
Other 
If other, please give additional details below 
List of reasons for withdrawal drawn from Mills et al.78
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Appendix 9 Case report form: University College
Hospital, London
Case Report Form
Developing a Stepped Approach to Improving Sexual Function after 
Gynaecological Cancer: 
a feasibility study.  (SAFFRON) 
Study ID:   …………………………….. Date (dd/mm/yyyy): …………………
DEMOGRAPHICS 
1.1. Date of Birth
1.2. Age years 
1.3. Ethnicity
(please tick one)







White & Black African 
White & Asian 
Other mixed 
background













Other (please specify below) 
_______________________
1.4. Living Situation 
(please tick one)
Living alone 
Living with partner 
Living with others (children, relatives etc.) 
D D M M Y Y Y Y
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A level (or equivalent) 
HNC/HND (or equivalent)
NVQ (or equivalent)
GCSE (or equivalent) 
No qualification
Other (Please specify): 
_________________________
1.6. Employment status 
(please tick one)
    Full time
    Part time
    Unemployed - seeking work 
    Unemployed - not seeking work
    Home maker 
    Retired
    On sick leave 
    Student 
    Other (Please specify): 
DISEASE RELATED INFORMATION
1.7. Type of Cancer: 
1.8. Stage of disease (FIGO)
1.9. Histological type
1.10. Date of primary diagnosis
(dd/mm/yyyy) 
    /             / 
1.11. Disease recurrence Yes    No 
Date (if applicable) (dd/mm/yyyy)
___________________________
1.12. Menopausal status at diagnosis
(Menopause = 12 months without a 
period) 
    Pre-menopausal
    Post-menopausal 
    Unknown
_________________________
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If yes, which one     Renal disease 
    Cardiac disease 
    Respiratory disease 
    Rheumatic disease 
    Diabetes
    Liver disease 
    Other (specify) 
_______________________________
TREATMENT RELATED INFORMATION 
1.14. Surgery Yes    No 
1.15. Mode of surgery     Laparotomy
    Laparoscopy 
    Vaginal 
1.16. Organs removed     Uterus
    Ovaries/ adnexae 
    Pelvic nodes 
    Para aortic nodes 
    Omentum 
    Vagina
    Vulva 
    Other 
1.17. Radiotherapy Yes    No 
1.18. Mode of radiotherapy     External
    Brachytherapy 
Other (please specify): 
1.19. Chemotherapy Yes    No 
Number of cycles given:
1.20. Hormone Therapy Yes    No 
_______________________________
_______________________________
1.13. Co-morbidity Yes    No 
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1.21. Other form of therapy 
Please Specify: 
1.22. Date of first primary treatment 
(dd/mm/yyyy)
/    / 
1.23. Date of completion of last
treatment (dd/mm/yyyy)
     /                / 
ECOG/ WHO Performance Status 
Fully active, no restrictions on activities
Unable to do strenuous activities, but able to carry out light housework and sedentary activities 
Able to walk and manage self care, but unable to work. Out of bed more than 50% of waking
hours
Confined to a bed or chair more than 50% of waking hours. Capable of limited self-care
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Appendix 10 Case report form: Bristol
Case Report Form 
Developing a Stepped Approach to Improving Sexual Function after 
Gynaecological Cancer: 
a feasibility study.  (SAFFRON) 
Study ID No:   ……………………………..
Socio-Demographic Information 
Highest level of educaon completed
Less than compulsory school educaon
Compulsory school educaon











Living with others (children, relaves)
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Disease-Related Information 
Type of Cancer: 
Stage of disease (FIGO): 
Histological type: 
Date of primary diagnosis (dd/mm/yy) ../../....
Disease recurrence: Yes No
Date of disease recurrence (if applicable) (dd/mm/yy) ../../....












Other (specify)     ………………………………………………………………………
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Treatment Related Information 






Uterus                                                                     Yes No
Ovaries/adnexae                                                   Yes No
Pelvic nodes                                                           Yes No
Para aorc nodes                                                  Yes No
Omentum                                                              Yes No
Vagina                                                                     Yes No
Vulva                                                                 Yes No
Other                                                                       Yes No
Radiotherapy
External                                                                   Yes No
Brachytherapy      Yes No
Chemotherapy                                                      Yes No
Number of cycles given if yes                                             
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Hormonal Therapy                                                Yes No
Other (specify)                                                               ………………… .
Time since end of primary treatment (dd/mm/yyyy)             ../../....
Date of compleon of last treatment (dd/mm/yyyy)             ../../....
ECOG/WHO Performance Status
Fully active, no restrictions on activities 
Unable to do strenuous acvies, but able to carry out light housework and 
sedentary activities 
Able to walk and manage self-care, but unable to work.  Out of bed more than 50% 
of waking hours 
Conﬁned to bed or a chair more than 50% of waking hours.  Capable of limited 
self-cares
Completely disabled.  Totally conﬁned to a bed or chair.  Unable to do any self-care 
Death 
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Appendix 11 Evaluation and Satisfaction Form
Evaluation and Satisfaction
Study ID  ………………………………………………….. Date ………………………………………
1. Overall, how are you compared to before treatment? 
Very much beer 
Much beer 
A lile beer 
About the same 
A lile worse 
Much worse 
Very much worse 
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For quesons 3 to 5, only parcipants who received the Level 2 intervenon should answer. 
Queson 3 asks about session one, Queson 4 about session two, and Queson 5 about 
session 3. Please ensure you answer in relaon to each speciﬁc session. 
Session 1 
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4c. Did you read the material aer your session/ do the worksheets?
Yes 
No
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5c. Did you read the material aer your session/ do the worksheets?
Yes 
No
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Appendix 12 Patient-held treatment diary
Treatment Diary
Instructions
Over the coming months you may attend different medical appointments with doctors,
nurses, and psychologists. While you are part of the SAFFRON trial you will be asked to
tell us how many times you attended appointments, and what health professional you saw.
This is to enable us to carry out a cost analysis of the support we are offering, to see if 
SAFFRON offers value for money. 
Therefore, please use this diary to write down all of your appointments that you attend 
over the next 8 months. Keeping a record in this diary will make it easier for us to collect
this information when it is required. 
You will be asked to give us this information at two points: 1) 25 weeks after you agree 
to be part of the study and 2) 8 months after you agree to be part of the study.
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Current Medication 
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Appointments 
This table is here to help you make a note of all the appointments you have in the coming
months. 
Any medical appointments that you have (including privately funded ones) should be
noted. 
Date  Health Professional 
seen
Site (e.g. GP surgery,
Walk in Centre etc.)
APPENDIX 12
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Date  Health Professional 
seen
Site (e.g. GP surgery, 
Walk in Centre) 
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Appendix 13 Patient interview schedule
Patient Interview Topic Guide 
Title of Project: Developing a Stepped Approach to
Improving Sexual Function after Gynaecological Cancer:  
a feasibility study.  (SAFFRON) 
Introduction for Patients 
Suggested script for researcher: This research aims to provide intervent ions to women experiencing
sexual diﬃculty after treatment for gynaecological cancer and assess the feasibility of conducng a 
larger trial of its eﬀect iveness. We wish to understand through the eyes of the pat ient the experience
of part icipat ing in the trial and receiving novel treatments while on the study.
Researcher: Reassure pat ient that they do not have to answer any quest ion they feel uncomfortable
with and they can stop the interview at any t ime. This will in no way aﬀect their care. 
Researcher: Emphasise that this is about get ng their views across & that all responses are  
anonymised & conﬁdent ial. Responses will not be shared with their health care team. 
Researcher: Talk through pat ient informat ion sheet if pat ient/wishes
Record date, patient ID
I’d like to start by asking you about your condition and your care. 
1 Could you brief ly tell me about your cancer and the treatments you received, and 
the most important ways that they af fect you?
Encourage focus and impact on quality of life 
2 What types of care do you currently have for your cancer?
Encourage brevity and focus on major health (+/- psycho-social care) intervent ions
3 Can you describe how you heard about the study
By poster/leaf let; word of mouth; Dr or nurse in clinic. 
4 Can you describe how you made the decision to consent to be screened to enter
the trial?
As appropriate, probe to clarify:
Who were the main people involved in present ing the study and assist ing 
you to make the decision? 
Were all aspects of the trial made clear to you at this t ime? If not, what was 
missing.
Were there aspects of the trial as described to you that you felt more or less
comfortable about? 
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5 All women on the study received psycho-educational materials. Please can we talk
in more detail about the beginning of your time on the study when you first 
received the psycho-educational materials? 
Can you describe how it was when you received this information? Can you tell us
the factors that influenced you positively? 
As appropriate, probe:
Overall did you find these materials helpful?  Would you recommend them
to someone else? 
Were you able/unable to express your views / ask questions? 
Were your preferences/wishes regarding your care taken into account at
this time? 
Which if any factors made a difference to how you took up the information; 
whether you used it afterwards? Why?
Any perceived concerns / benefits eg nature of psycho educational 
materials; the way they were introduced etc; 
Extent to which uptake of materials was influenced by personal
characteristics e.g. belief systems, autonomy, etc.  
Extent to which personal characteristics interacted / were mediated by
context e.g. their relationship with key health professionals / being part of
the trial; uncertainty surrounding management options for their cancer and
getting help for sexual difficulties etc.
6 If woman was on control arm:
How did you feel when you heard that you would not receive the new treatments?
Probe:
Did the offer of ‘treatment as usual’ seem fair to you?
Did the initial materials pack help you? Did you feel that you had benefitted 
from the materials even though you had not had access to the full 
nurse/psychology delivered treatments?
Would you have preferred to be in the treatment arm of the trial?
7 If woman was on treatment arm 
What treatments did you receive? Nurse only? Psychology only? Both?
Probe:
What was the experience of treatment like? Helpful? Difficult? Explore the 
time issues, arrangements for therapy issues including travel; burden on
family; benefit / or worsening of relationship with partner, family members,
other; increased understanding of self/body/sexuality; understanding of 
what is normal after treatment for cancer; 
Was there a difference for you between the nurse sessions and the 
psychology sessions (if had both)? If so, can you say what it was? 
Which treatment did you find most helpful? Can you try to explain why? 
If you had the opportunity to choose one of the treatments you received, 
which would it be? Can you try to explain why? 
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8 ALL WOMEN 
Is there anything about being on the trial and your care that you know now, that
you would like to have known before/when your participation first began? 
As appropriate, probe:
To know the details of the questionnaires
If in trial arm - Time in counselling/psychotherapy, recuperation issues, 
communication with the MD clinical team; impact on partner etc.  
How might this information have changed your decision to participate?
In the trial, patients are recommended to change to more or less 
intensive treatments based on their final score to answers on a 
questionnaire that asks directly about sexual function
9 What were your experiences of completing this questionnaire and receiving your
score?
As appropriate, probe:
How was the score given; opportunity to discuss score and your feelings in
relation to it? 
What were your preferences/wishes regarding your care? 
10 All WOMEN 
During the trial you were asked to complete a number of questionnaires at
different time points. Can you tell me how that was for you? 
As appropriate, probe:
Number of questionnaires;
assistance to complete; purpose not clear; 
suitability of questions/questionnaires; 
any questionnaires/particular questions that presented difficulty. 
11 ALL WOMEN 
Did you understand the idea of ‘stepped care’ within the study?
As appropriate, probe:
Was it explained to you? 
Did you experience being ‘stepped up’? If so, how did you understand the 
reasons?
Do you think you got the level of care/intervention that was right for your 
difficulties?
Of all the help you received as part of the research, which did you find
most helpful?  Was there anything offered that you found unhelpful? 
Can you try to explain why?
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12 ALL WOMEN 
What were/are the important things about your experiences during the trial that
you would want the research team to consider when planning a larger trial?
As appropriate, probe:
Defined benefits & concerns e.g. effects of treatments. 
Intervention specific issues e.g. quality of life (pain, impact on relationship
and independence/dependence etc); 
Timing and settings for treatment delivery; length of talking therapies;
adjustment time when treatment stops; enormity of difficulties; quality of 
life etc. 
13 ALL WOMEN 
What information should be fed back to you about the results of this trial?
As appropriate, probe:
Factors which influenced participants to consent; 
Why patients withdrew; 
Other patients experiences; 
Views of the staff involved;
Feasibility.
Finally, is there anything else about how patients are involved in the 
trial and receive their care that you would like to add?
APPENDIX 13
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
Appendix 14 Staff interview schedule
Staff Interview Topic Guide 
Title of Project: Developing a Stepped Approach to
Improving Sexual Function after Gynaecological Cancer:  
a feasibility study.  (SAFFRON) 
Introduction for Staff 
This research aims to provide interventions to women experiencing sexual difficulty after treatment
for gynaecological cancer and assess the feasibility of conducting a larger trial of its effectiveness.
We wish to understand the trial processes through the eyes of relevant staff.
Researcher: Reassure staff that they do not have to answer any question they feel uncomfortable 
with and they can stop the interview at any time. 
Researcher: Emphasise that this is about getting their views across & that all responses are 
anonymised & confidential. Responses will not be shared with their health care team colleagues or
with trial participants.
I’d like to start by asking you about your role. 
1 Could you briefly tell me about your role in the Trust? 
Encourage to highlight overall responsibilities and those in relation to
gynaecological cancer patients. 
Try to establish level of experience.
2 What do you think the general aim of the study was?
3 Could you tell me about the aspects of the trial you have been responsible for 
or have been involved with? 
Encourage brevity & focus. 
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4 Would you say that this feasibility trial was a satisfying experience for you and 
if so, can you say how/why?
Encouraged to expand. 
5 What were the least satisfying aspects?
Different kind of work with patients; intensity of study interventions; initial 
screening questions; recruitment process; impact on clinic space/overall
service; equity issues.  
Please can we talk in more detail about the aspects of the trial you are involved
in? 
Questions selected so that they are relevant to the informant’s role and 
experience
Study-trained nurses, radiographers and psychologists
6 Before you began the study, what did you expect the interventions would be like? 
Probe:
How did you feel about taking on this role? 
In what ways do you think you were prepared/unprepared for the role? 
Have your feelings about your preparedness changed as you have 
delivered the intervention? 
7 What was your experience of doing the study as a nurse/psychologist?
Probe:
Experiences of care and negotiating with patients 
Did you experience any difficulties in meeting patients’ expectations for 
care while on trial? 
How do you think things might be different/better in this respect? 
Women’s responses to you
Particular concerns/difficulties in relation to the intervention you 
provided? 
How did you find using the FSFI to evaluate and focus sessions? 
Was the manual helpful? 
How did you find working with a manualised intervention? 
Did it constrain your normal style/ enable more material to be 
covered/offer new ways of working?
Did you experience any difficulties delivering the intervention in
accordance with the manual? 
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What was your experience of the training to deliver the interventions? 
Did the training provide sufficient preparation for the role? 
Which aspects of the training were most helpful, which aspects were least 
helpful? 
Were there things you would like to have covered in the training that you did 
not? Was there any aspect of the training that you thought unnecessary? 
How did you experience supervision?
Were the sessions helpful? Was the format appropriate?
What do you think may have helped you more? 
Nurses/Radiographers 
You were asked to deliver an essentially psychological intervention. What
was the experience of working in this way for you?
Explore if – more difficult at first? Anxiety provoking? Interesting/enriching practice?
Psychologists 
You were asked to deliver a version of IPT. Had you been trained in IPT 
before? How different was this style from other ways of working that you 
have used with similar patients in the past? 
How was the experience of working to a manual? Constraining? Helpful to focus?
Anxiety re keeping to manual? 
Has working to deliver the trial interventions been different to the way you 
usually work as a CNS/psychologist? If so in what ways? 
Did you experience difficulties in doing this? If so what were they? 
Clinical team members including non study-trained
nurses/radiographers
What was the experience of raising sexual concerns directly with patients
like for you?
Did you experience difficulties in doing this? If so what were they? Did it alter the 
nature of your contact with the patient? At the first point of discussion? Did you
continue to discuss sexual concerns if a patient had them after referral into study? 
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Did the study conflict with normal care and clinic running? 
Probe:
Was your experience of the study that it helped normal care, changed 
it, or made things more difficult?
Service Managers
Were you aware of the study running in the clinic? What impact did it have 
from your point of view as a manager?
Probe:
Did the study conflict with normal care and clinic running? 
Was your experience of the study that it helped normal care, changed 
it, or made things more difficult?
Finally, is there anything else about how patients are involved in the trial and 
receive their care that you would like to add?
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